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Quitting Patterns and Success Rates of a Tobacco
Cessation Program Led by New Mexico Pharmaceutical
Care Foundation

By
Xian Shen
B.S., Pharmacy, China Pharmaceutical University, 2010
M.S., Pharmaceutical Sciences, University of New Mexico, 2012
ABSTRACT
The objective of the present study was to assess the effectiveness of a
pharmacists-assisted tobacco cessation program led by New Mexico
Pharmaceutical Care Foundation (NMPCF) and to characterize participants’
quitting patterns during the study period.
Data from the program from 2004 to 2011 consisting of 1486 participants
were combined for analysis. Point prevalence quit rates were calculated and
survival analysis was performed to evaluate program effectiveness. A qualitative
case study with participating pharmacists was conducted to explore intervention
elements that could impact participants’ likelihood of successfully quitting
tobacco. Four quitting patterns were defined including immediate quitters,
delayed quitters, once quitters, or never quitters. Multinomial logistic regression
was performed to identify patient characteristics associated with quitting patterns.
The average point prevalence quit rate at 6 months was 18.7%. The
average abstinent time was 76.8 days (standard error = 3.59 days). The
iv

probability of a patient being continuously abstinent for 7 days was 89.1%, while
the likelihood of being abstinent for 30 days and 180 days were 46.0% and
16.5%, respectively. Patients who were under 18 years old, less educated, less
dependent on nicotine, and had higher confidence to quit were more likely to be
immediate quitters rather than never quitters.
Pharmacists are capable of delivering tobacco cessation services.
Patients’ likelihood of quitting tobacco depends both on themselves and the
intervention they receive. Intensive counseling and close follow-up are important
elements of an effective tobacco cessation intervention. Different quitting
patterns exist among patients. Patients with different quitting patterns have
distinctive characteristics in terms of level of nicotine dependence,
pharmacotherapy used, motivational factors and demographic factors.
Interventions need to be tailored for patients with different quitting patterns.
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Chapter 1 Introduction
Background and problem statement
Tobacco use is a known cause of multiple cancers, heart disease, stroke,
complications of pregnancy, and chronic obstructive pulmonary disease
(COPD).1 It remains the chief avoidable cause of death in the United States,
accounting for more than 435,000 deaths each year.2 Furthermore, smoking
results in approximately $100 billion in health care costs and another $97 billion
in lost productivity in the United States every year.3 Despite the well
acknowledged harms of smoking and its economic burden, the 2006 National
Health Interview Survey (NHIS) suggested that the prevalence of cigarette
smoking among the U.S. adults was approximately 21%.4 Smokers are aware of
the health dangers of tobacco use and struggles to quit the habit. Around 70% of
the smokers who participated in 2000 NHIS reported that they wanted to quit,
and 41% had tried to quit during the preceding year.5 Another study showed that
almost two thirds of smokers who did not successfully quit were interested in
trying to quit again within 30 days.6

However, quitting using tobacco is a difficult task with multiple barriers. Weight
gain, craving for smoking, loss of pleasure, stress and depression after quitting
as well as being around smokers, have been reported as the most common
reasons for relapse.7, 8 9, 10 Overcoming these barriers without health
professionals intervention and pharmaceutical aid is challenging. There has been
evidence showing that patients who received advice and assistance for quitting

1

tobacco during their physician visits had better satisfaction about their care 11 and
smokers take physicians’ advice as an important motivator for attempting to
quit.12 A meta-analysis from Cochrane showed that success rates of self-help
interventions ranged from 2% to 10%, which were slightly higher than that of no
intervention (pooled relative risk=1.21; 95% C.I. 1.05-1.39). 13 Another metaanalysis indicated that behavioral interventions delivered by health care providers
were more effective compared to interventions where no health professional was
involved. More importantly, the success of interventions did not differ by type of
clinician. Physicians (estimated quit rate= 19.9%; 95% C.I. 13.7%–26.2%) and
other clinicians (estimated quit rate=15.8%; 95% C.I. 12.8%–18.8%) were almost
equally successful in helping smokers quit.14

Strategies of interventions have been designed to assist clinicians with
counseling both smokers who are ready to quit and smokers who are reluctant to
quit. The 2008 Clinical Practice Guideline for Treating Tobacco Use and
Dependence recommends a brief clinician led intervention to be offered to all
tobacco users using the “5 A’s” strategy (Ask, Advice, Assess, Assist, Arrange).
For patients who are unwilling to quit, a clinician should provide a motivational
intervention, consisting of five major components (“5 R’s”, relevant, risk, rewards,
roadblocks, repetition). In addition to brief counseling, the guideline also
recommends tobacco cessation products be offered to all smokers attempting to
quit except when contraindicated and for specific populations among whom the
effectiveness of the products is unclear. A combination of counseling and
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pharmacotherapy is more effective than counseling alone or pharmacotherapy
alone. 14 First-line agents, including bupropion sustained-release (bupropion SR),
nicotine replacement therapy (NRT), and varenicline, are effective in a broad
range of populations.15, 16

Despite the potential contributions that clinicians could make to tobacco
cessation and the availability of well-developed interventions, counseling on
tobacco cessation does not take place in day-to-day health care settings.
According to the National Committee for Quality Assurance’s (NCQA) 2007 State
of Health Care Quality Report, 73.8% commercially insured smokers and 68.2%
Medicaid smokers received advice to quit in 2006. Counseling about quitting only
happened to 43.2% commercially insured smokers and 36.7% Medicaid
smokers.17 Physician counseling occurred in 21% of smokers’ visits in 200318
and lack of time was reported as a central barrier to counseling by physicians.19
Compared to physicians and other clinicians, pharmacists are relatively more
accessible to patients.20 Their unique position in the health care system allows
them to identify smokers who are willing to quit and assist them throughout the
quitting process. Pharmacists in New Mexico have been granted more authority
and might play even a greater role in tobacco cessation than their peers in other
states. With an approved protocol, they could prescribe tobacco cessation
products, which makes it possible for them to help tobacco users quit more
directly.21 More importantly, pharmacists are also interested in providing tobacco
cessation services and see it as an important activity of their profession.22, 23 In
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order to strengthen pharmacist’s capability of counseling tobacco use, efforts
such as the Rx for Change program have been established to expand tobacco
cessation training among pharmacy students as well as licensed pharmacists.24
The Rx for Change curriculum has been disseminated to pharmacy schools
throughout the U.S. and has already obtained acceptance and positive
feedback.25

Studies have been conducted to demonstrate the effectiveness of pharmacistsled tobacco cessation interventions. A Cochrane review identified two
randomized controlled trials of pharmacists-assisted tobacco cessation programs
in U.K., which showed a continuous abstinent rate of 18.5% at 6 month and 12.0%
at 9 month, respectively. 26 Observational studies with varying designs of
intervention have also demonstrated the effectiveness of pharmacists-delivered
services.27 A successful quit depends on the smoker as well as the intervention
received. While characteristics of successful quitters have been extensively
studied in various populations, the impact of intervention elements on one’s
likelihood of success remains understudied. A few studies compared
interventions using quantitative approaches. Elements including intensity of
counseling, format of counseling and number of counseling formats adopted,
combination of counseling and medication, and intervention setting have been
shown to be associated with success rates. 14, 28, 29 Nevertheless, research on
intra-intervention level, aiming to understand within-study difference, is rare. We
have very limited knowledge on the reasons why some clinicians are more

4

successful in helping smokers quit than others in the same cessation program
and their perception of their success.

While quit rates of various interventions have been reported previously, the
process of quitting remains understudied. Few studies have presented a
comprehensive picture of how patients’ post-intervention smoking behaviors
changed over time or how the final point prevalence quit rate was reached.30
The transtheoretical model of change (TTM) is the most widely known theory of
health behavior change and has been applied to guide tobacco cessation. It
proposes that tobacco users move through 5 stages before they successfully
achieve abstinence.31 The stages are “precontemplation” (not thinking about
quitting), “contemplation” (thinking about quitting), “preparation” (planning to quit
in the next 30 days), “action” (quitting successfully for up to six months), and
“maintenance” (no tobacco use for more than six months). The process of
quitting tobacco is complicated, during which patients might return from
advanced stages like “action” to earlier stages such as “preparation”. Moreover,
patients in the “preparation”, “action”, or “maintenance” stage of quitting would
require different types of support from those in “precontemplation” or
contemplation”. Therefore, quitting tobacco is a process that requires
interventions tailored to patients’ stage of quitting and it also takes repeated
efforts to reinforce treatment effects. Point prevalence quit rate does not
represent such a continued and complex process. In order to better understand
the process of quitting and improve future interventions, quitting patterns and
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smokers’ transitions in smoking behaviors that emerge during the quitting
process need to be evaluated in more details. Predicting tobacco users’ quitting
pattern and transitions will also provide clinicians with more information about
how patients move between the stages after/during intervention, which in turn,
will help them better assist patients in quitting tobacco.
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Study question, specific aims and hypotheses
The primary objective of the present study was to assess the effectiveness of a
pharmacists-assisted tobacco use cessation program led by New Mexico
Pharmaceutical Care Foundation (NMPCF) and to characterize participants’
quitting patterns during the study period. We proposed four specific aims to be
accomplished by this study.

Aim 1: To calculate 1 month, 3 months, and 6 months point prevalence quit rates
of the NMPCF tobacco cessation program.
Aim 2: To study participants’ probability of being continuously abstinent and their
quitting experience over time.
Hypothesis 1: Participants’ likelihood of being continuous abstinent was
associated with patient characteristics including age, gender, ethnicity,
education level, tobacco use, past quitting attempt, pharmacotherapy use,
nicotine dependence, confidence to quit, and importance to quit.
Aim 3: To identify quitting patterns among participants and compare participants
of different quitting patterns with respect to pharmacotherapy use and other
baseline characteristics.
Hypothesis 2: Participants’ quitting patterns were related to patient
characteristics including age, gender, ethnicity, education level, tobacco
use, past quitting attempt, pharmacotherapy use, nicotine dependence,
confidence to quit, and importance to quit.
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Aim 4: To assess the variation in success rates among pharmacy stores, and to
explore elements of effective tobacco cessation services.
Hypothesis 3: Pharmacy stores had varying point prevalence quit rates at
1 month, 3 months, and 6 months.
Hypothesis 4: Quit rates were affected by intervention elements such as
intensity of intervention sessions, frequency of follow-ups, and format of
counseling.

8

Chapter 2 Literature review
Three systematic Medline reviews, with respective focus on effectiveness of
pharmacists-assisted tobacco cessation interventions, quitting patterns, and
significant predictors of successful abstinence, were performed. The search
strategies and the existing literature were summarized for each topic.
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Effectiveness of pharmacists-assisted tobacco cessation programs
The literature search was performed up to January, 2012, restricting to English
and human literature. The MeSH term “pharmacists” was combined with the
MeSH term “tobacco use cessation” in the search. Original studies on
pharmacists-assisted tobacco cessation programs with data analysis of quit
rate(s) were eligible. We also added studies from reference lists of reviews.
Interventions in which pharmacists did not take an active role were excluded.
Editorials and perspective articles were excluded. The search produced 69
citations, among which 6 original studies and 2 reviews were identified. Another
three original studies were identified from the reviews. Included studies were
summarized by intervention, outcome and sample size (Table 1). Compared to
the other programs, the one offered by Missoula Veteran Affair Veteran Health
Administration outpatient clinic in Missoula, Montana achieved extremely high
long-term abstinence rate.32 The program was administered by a pharmacy
specialist and offered about 4 to 5 times per year depending on the number of
referred patients. One hundred and thirty veterans participated in the program
during 2001-2003. At the follow-up telephone surveys completed in June and
December of 2001, 2002, and 2003, 41.5% of them continued to be abstinent
after the end of the program with 54 for 6 months, 42 for 1 year, 27 for 2 years,
20 for 3 years, and 4 for 4 years. The success was related to the proper design
and delivery of the program. Before admitting veterans into the group class
sessions, an initial assessment of their motivation to quit was conducted and a
one-to-one motivational counseling using 5“Rs” was delivered if the veteran was
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in precontemplation and unwilling to quit. Moreover, the 3 group class sessions
were designed based on the Transtheoretical Model of Change with specific
focus on preparing smokers to quit, assisting smokers to take action, and helping
them to maintain abstinence. Pharmaceutical aids were also offered to
participants without any charges in conjunction with the group counseling
sessions. This was a perfect example proving that pharmacists could deliver
effective tobacco cessation services given the intervention was well planned and
designed based on evidence.
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Table 1 Summary of Pharmacists-assisted Tobacco Cessation Programs from Literature
Reference
Zillich et al
(Pharmacothepray
2002)

Number of
participants
31 selfreferred

Roth et al
(Pharmacotherapy
2001)

71 referred
by physician

Kennedy et al (J Am
Pharm Assoc 2002)

48 identified
by
community
pharmacist
or referred
by physician
2,001
participated
in the
Pharmacists
Educating
Patients
Program
1374 invited
by letter

Smith et al (Am
Pharm 1995)

Bauld et al (Nicotine &
Tob Res 2011)
Costello et al (Cancer
Causes Control 2011)

3588

Maguire et al
(Addition 2001)

484 enrolled
by
pharmacists

Roth et al
(Pharmacotherpy
2005)

198 referred
by physician

Intervention

Outcome

Weekly group session for 12
weeks led by pharmacist(s);
nicotine replacement therapy
(NRT) paid by participants;
follow-up via phone
Counseling with clinical
pharmacist; educational
booklet; bupropion SR;
phone follow-up; 3 clinic
visits
Counseling with community
pharmacist;
pharmacotherapy paid by
participants; face-to-face
visits/phone follow-up

*Verified abstinence at 3
and 6 months: 42% and
26%

Counseling with pharmacist;
NRT (transdermal)

Self-reported abstinence
at 10 months: 33%

One-to-one counseling with
pharmacist for 12 weeks;
pharmacotherapy;
3 sessions of pharmacistsled behavioral intervention; 5
weeks NRT

*Verified continuous
abstinence at 52 weeks:
3.6%
Self-reported point
prevalence abstinence
rate at 7 day: 27.7%

Booklet and a one-to-one
counseling with pharmacist at
baseline; weekly follow-up for 4
weeks and then monthly for 3
months with pharmacist

*Verified continuous
abstinence at 12
months: 14.3%

Tailored behavioral
counseling with pharmacist;
educational materials;
pharmacotherapy; follow-up
via phone/visit
Dent et al (J Am
130 veteran 3 session counseling using
Pharm Assoc 2004)
self-referred the Transtheoretical
or referred
Model of Change with
by physician pharmacist;
pharmacotherapy
*Verified by exhaled carbon monoxide test or continine
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Self-reported continuous
abstinence at 8 weeks
and 6 months: 15.5%
and 9.9%
Self-reported continuous
abstinence at 12
months: 25%

Self-reported continuous
abstinence rate for NRT
and bupropion SR:
22.9% and 7.7%
Self-reported continued
abstinence (6 months-4
year): 41.5%

Comparing the interventions and outcomes of these 9 studies, group sessions
and intensive interventions appeared to be more effective than interventions
conducted individually or without close follow-up. However, the observed
difference could also be associated with differences in study samples. The
success rate of the program reported by Zillich et al33 was more than 5 times
higher than that of the program reported by Bauld et al34. However, the
participants in the program Zillich et al described seemed to be more motivated
to quit compared to the participants in the other program. On average they had
tried to quit 3.2 times and paid for pharmacotherapy by themselves. None of the
9 studies analyzed time to relapse or presented quit rate on a longitudinal basis.
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Quitting patterns
The literature search was conducted up to January, 2012, restricting to English
and human literature. The MeSH term “tobacco use cessation” was combined
with the keywords “pattern*” and “quit”. We were interested in studies assessing
quitting patterns or relapse patterns during or after a tobacco cessation
intervention. Studies concentrating on smoking patterns or usage patterns of
medications, services or programs were excluded. The search gave 296
citations and abstracts were reviewed to determine the eligibility of each article.
We identified 4 studies evaluating quitting or relapse patterns and 1 study
assessing reduction pattern.

Gonzales et al pooled data from two identically designed clinical trials of
varenicline versus bupropion sustained-release and placebo, and described two
types of successful quitters, which were immediate quitters (IQ) and delayed
quitters (DQ).30 In both trials, participants received 12-week treatment and were
followed up for 52 weeks. The primary end-point of the trials was continuous
abstinence for weeks 9-12 and the target quit date (TQD) was day 8 followed the
first week treatment. IQ achieved initial abstinence immediately on the day 8
TQD and remained continuously abstinent for weeks 2–12. QD were those who
quit later than the TQD or those who experienced lapses between TQD and
week 9, but were then able to achieve continuous abstinence for weeks 9–12.
They found that the proportion of DQ among successful quitters was similar
across treatments and DQ were less likely to remain abstinent at 52 weeks

14

compared to IQ. Hajek et al analyzed data from a clinical trial of 12-week
extended treatment of varienicline and showed that DQ were more likely to
benefit from the extended treatment compared to IQ.35 They randomized a total
of 1208 IQ and DQ who were abstinent at least for the last week of a 12-week
varenicline treatment to either 3 months continued treatment with varenicline or
placebo. The extended course of varienicline was effective in preventing DQ from
relapse at 52-week (odds ratio (OR)=1.7, 95% confidence interval (95% C.I.):
1.2-2.4), but such effect was not seen among IQ (OR=1.1, 95% C.I.: 0.8-1.5). In
addition, they also found smokers who initially delayed to achieve abstinence to
be more likely to relapse at 52-week after adjusting baseline characteristics as
Gonzales et al described. The results of above two studies indicate that DQ need
prolonged treatment to reinforce treatment effects. This information is valuable
for tailoring individualized interventions and improving effectiveness as well as
efficiency of future programs. Both of the studies were restricted to
pharmacotherapy and the generalizability of these findings to other tobacco
cessation interventions was not clear.

There also have been studies evaluating patterns of smoking reduction, lapses
during quitting attempts, and resumption after relapse. Estabrooks et al
concluded that initial successful reduction was associated with final success.9
Conklin et al identified 4 patterns of smoking resumption after relapse including
low-lever users, moderate users, slow returners, and quick returners. 36 Ussher
et al found that patients using 16 hour nicotine patches were more likely to lapse

15

during afternoons and evenings than in mornings (p<.0001).37 Of the 5 studies
identified, only Gonzales et al presented the baseline characteristics of IQ, DQ,
and all sample, but no extensive analysis was done to characterize the two
patterns they defined.
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Significant predictors of successful abstinence
The literature search was conducted up to January, 2012, restricting to English
and human literature. The MeSH term “tobacco use cessation” was combined
with the keyword “predictors”, “reasons”, or “characteristics”. We limited the
search to studies that evaluated characteristics of successful quitters or elements
of effective interventions. The search yielded 595 citations and the abstract of
each article was reviewed to determine the eligibility of articles. We excluded
studies on smoking behaviors, characteristics of smokers, effectiveness or
utilization of interventions, services or pharmacotherapies, and reasons, intention,
motivation, or attempts to quit. In order to increase relevance of the review to the
present proposal, studies focused on a particular population such as cancer
patients or pregnant women were further excluded as well as studies whose
sample consisted of smokers who did not attempt to quit. Ninety-one studies met
the above inclusion criteria. With exception of two studies evaluating intervention
elements, almost all the studies focused on identifying characteristics of
successful quitters. Eight domains of predictors were identified from the literature.
Non-significant predictors were not included in the following discussion.

1) Use of pharmacotherapy
Tobacco cessation products approved by the Food and Drug
Administration (FDA) include NRT, bupropion sustained release (Zyban®,
Wellbutrin®), and varenicline tartrate(Chantix®).38 Other than clinical trials
specifically designed to study efficacy of tobacco cessation products39-42,
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prior evaluations of tobacco cessation programs also demonstrated that
use of pharmacotherapy was effective and independently predicted
successful cessation. Results from a behavioral intervention among
elderly smokers showed that smokers who used NRT were 4.36 more
likely to quit than those who did not receive NRT.43 Adherence was low
among smokers who were using NRT to quit, but adherence to NRT was
found to be predictive of successful cessation.44 A retrospective analysis
of abstinence outcomes of enrollees of a quitline service showed that
smokers who used varenicline tartrate were 1.85 times more likely to quit
at 3 month follow-up compared to smokers who used NRT after controlling
for age, gender, previous amount of tobacco use, and number of
counseling calls.45 In a study of 285 patients who attended a tobacco
cessation clinic, patients in the bupropion sustained release (SR) group
had 2.89 times increased odds of being continuously abstinent at 6 month
compared to those in the placebo group.46 Other studies also found use of
bupropion SR independently predictive of tobacco cessation.46-49

2) Nicotine dependence
A couple of variables have been used as measures of nicotine
dependence including score of Fagerstrom Test of Nicotine Dependence
(FTND) , age when first started smoking, average number of cigarettes
per day, and time to first cigarette after waking. FTND is a validated
questionnaire used to measure smokers’ level of nicotine dependence,
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which consists of six items (see Appendix A for the full questionnaire).50
Scoring per item is either a two or four level response with values 0, 1, 2,
or 3. Items are summed and the possible scores range from 0 to 10.
Previous studies categorized FTND differently, but it has been consistently
found to be independently predictive of successful quits in various
studies.51-54 In a non-randomized clinical trial, participants who with FTND
score greater than 8 were 1.63 times more unlikely to succeed in quitting
smoking at 1 year compared to those with FTND score less than 4.53
Number of cigarettes consumed per day and time to first cigarette after
waking are two components of FTND. Both of them have been shown to
be indicative of likelihood of successfully quitting tobacco use.46, 55-61 An
analysis of a behavioral intervention in Italy found that smokers who
initiated smoking after 18 years old were 1.65 times more likely to quit at 1
year than other after adjusting for previous attempts, number of cigarettes,
education level, and age.57 Another study in Finland found starting at a
late age to be a significant predictor in male smokers, but not in female
smokers.56

3) Health perception and comorbidities
Health has been cited as the most predominant reason for wanting to quit
in surveys.62-64 A survey among German industrial employees was
conducted to study reasons of attempting to quit. Of 360 employees who
were in contemplation or preparation stage, 94% of them stated health
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risks as the reason for quitting, which predominated financial (27%) or
image-related (14%) reasons.64 A study conducted among an elderly, lowincome population Lebanon showed that having at least one chronic
illness and having a functional disability significantly increased the odds of
smoking cessation.65 Experiencing a health-related problem might change
patients’ smoking behavior. In a group of smokers who were newly
diagnosed with head and neck cancer in Florida, 62% of them planned to
quit smoking in the next 3 months 66, which is 20% higher than the
national percentage.5 A study of 717 smokers treated at an emergency
department (ED) revealed that having a smoking-related event, such as a
diagnosis of respiratory diseases, predicted 7-day abstinence within one
month after controlling for nicotine dependence, self-efficacy, and other
smoking-related variables, while presence of a smoking-related disease
was not a significant predictor.67 Another study even found having a
smoking-related disease was inversely related to abstinence at 7-week51,
although diagnosis of smoking-related diseases has been identified as a
strong trigger of smoking cessation.68

The role, which depressive symptoms or history of depression plays in
quitting process, is in dispute. Several studies have demonstrated that
smokers having depressive symptoms or a history of major depressive
disorders were less likely to quit smoking than others47, 49, 69, while a metaanalysis, which included 15 studies, showed that a lifetime history of major
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depression was not related to failure in smoking cessation treatment.70
Interaction between a tobacco cessation program, targeting rural teenage
smokers, and depression was suggested.71

4) Psychological factors
Previous studies have demonstrated that self-efficacy of smokers, and
their confidence and degree of motivation to quit are predictive of smoking
cessation. Typically, smokers’ self-efficacy is defined as confidence in
ability to refrain from smoking in negative affect situations such as being
with a smoker, and in habitual or craving situations.72-74 In a study of loweducated women who received a brief cessation intervention, 1 point
increase on a 4-point scale of self-efficacy was associated with doubling
odds of smoking cessation at one week.75 In some studies confidence to
quit at this time was used as a measure of self-efficacy and found to be
predictive of quitting as well.44, 76, 77 A study using a French measure of
motivation (Q-MAT) indicated that smokers with a score greater than 17
were 1.63 times more likely to quit than others.51 A qualitative study that
followed 15 adolescent smokers over 3 months found that reasons of
quitting were not equally motivating and successful quitters usually had
greater motivation.78

5) Previous attempts

21

A study of a 5-week group behavioral intervention found that attempting to
quit in the past was associated with 1.49 times increased odds of being
abstinent at 6 month post-intervention.57 Duration of past attempts has
also been found to be associated with current success after adjusting for
nicotine dependence, use of pharmacotherapy and demographic
characteristics, with longer previous attempt being indicative of success of
current attempt.51, 59, 69, 79

6) Social influence
A study of 1,335 adolescent smokers from six European countries
assessed the impact of social influence, measured by three scales
representing influences from family, friends, and others in the same school,
on smoking behaviors. 80 Each scale included 3 domains: a) social norm,
which assessed adolescents’ perceptions of whether it was important what
others thought (that they definitely should smoke or should not smoke); 2)
social pressure, which measured how often direct pressure to smoke was
perceived by adolescents; 3) perceived smoking behavior of others (how
many of social acquaintances smoked). The study showed that depending
on the country, social influences from family, friends and others in the
same school were related to adolescent smokers’ perception of smoking,
intention to quit, and successful quitting at 6 month. Other studies also
found that those with a social network discouraging smoking were more

22

likely to quit.81, 82 Lack of social support has been identified as a trigger of
relapse.83 A study of 1790 nurses using an online tobacco cessation
service showed that quitters were more likely to report support from
colleagues, working at a smoking-free facility, and having cessation
services at workplace.84 Not only smokers’ work environment, but also
their environment at home affects the likelihood of quitting. The presence
of a non-smoking partner or a partner who quits smoking significantly
predicts a smoker’s quitting behavior.39, 73, 85-87 Moreover, adoption of
smoking ban at home was also suggested to be effective in assisting
smokers to quit and preventing relapse.82, 88-90

7) Demographic factors
Previous studies also showed that smokers’ demographic and
socioeconomic characteristics were associated to chance of success. A
large number of studies included age in analysis and consistently found
that smokers with older age were more likely to quit than others.
79, 81, 88, 91-94

45, 47, 61, 69,

Being married was also consistently found to be associated

with cessation.51 Studies on gender difference in likelihood of quitting had
discrepant findings with the majority of the studies indicating that males
were more likely to quit92, 43, 57, 69, 94, 95. The literature also suggests
smokers with higher education level, income and social class are more
likely to quit. 44, 56, 59, 73, 93
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8) Intervention elements
We only identified two studies that evaluated the impact of intervention
characteristics on effectiveness of tobacco use cessation services. Both
studies assessed the smoking cessation services provided under the
National Health Service in UK, but with different analytic approaches.
Brose et al pooled the data from 126, 890 treatment episodes in the
English network of stop-smoking services (SSSs) and each treatment
episode was a unit of analysis.29 The characteristics examined included
setting, medication, and type of support. After adjustment for smokers’
characteristics, they found substantial variation in success rate across
service characteristics. Single NRT was associated with higher success
rates than no medication (OR 1.75, 95% CI 1.39 to 2.22). Combination of
NRT and varenicline was more effective than single NRT. Group support
was linked to higher success rates than one-to-one support (OR 1.43, 95%
CI 1.16 to 1.76). Primary care settings were less successful than specialist
clinics (OR 0.80, 95% CI 0.66 to 0.99). In contrast to Brose et al, the
investigators of the other study assessed the association between service
characteristics and quit rates on a service-level instead of a treatment
episode level. A survey was sent out to 133 service coordinators to obtain
information on service characteristics, areas where services were offered,
and outcomes of services measured by number of smokers reached and
cessation rate.28 The final analysis included 76 services and considerable
variation in cessation rates was found across services. They used
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ordinary least squares regression to characterize the relationships
between outcomes and area and service characteristics. Services in
health action zones, which were located in areas of high deprivation,
reached on average 140% more smokers than those in other parts of the
country. Services with strong relationship with local primary care
organizations reached more smokers. Number of intervention sessions,
group intervention, and strong relationship with local primary care
organizations were positively related to cessation rate, while services
operating in deprived areas achieved a lower cessation rate.
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Summary of literature reviews
The purpose of the literature reviews was to inform variable selection for the
statistical analyses of patients’ continuous abstinence and quitting patterns, and
to assist the design of the case study for exploring elements of effective
intervention. In summary, previous research in pharmacists-assisted tobacco
cessation programs indicates variations in intervention design as well as
intervention outcomes measured by quit rates. The majority of the existing
literature on predictors of successful tobacco abstinence focuses on patient
characteristics. Seven domains of individual characteristics were identified from
the literature review including pharmacotherapy use, level of nicotine
dependence, health perceptions and comorbidities, psychological factors (e.g.
confidence to quit), previous attempts, social influences from family and friends,
and demographic factors (e.g. age, gender). Patient characteristics from intake
questionnaire, if related to these factors, were included in the survival analysis as
well as the pattern analysis. Findings about elements of effective tobacco
cessation interventions from the two UK studies (e.g. type of pharmacy, format of
counseling, frequency and intensity of intervention) were incorporated into
developing survey questions for the case study with the pharmacists.
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Chapter 3 Methods
This study was a retrospective and longitudinal cohort of the patients participated
in the NMPCF tobacco cessation program with data collected over 7 years. The
study consisted of four parts, including quit rates calculation, survival analysis,
pattern analysis, and case study with participating pharmacists. Point prevalence
quit rates and patients’ continuous abstinence analyzed by survival analysis were
intended to evaluate the effectiveness of the tobacco cessation program. The
case study was adopted to explore variation in quit rates across pharmacies and
constituents of an effective intervention. The pattern analysis was aimed to
investigate the potentially existing quitting patterns among patients. The study
methods, results, and discussion were organized around these four essential
parts of the study.
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Data source
The data was from a pharmacists-assisted tobacco cessation program led by
New Mexico Pharmaceutical Care Foundation (NMPCF). NMPCF initiated the
program in 2004 and offered it every year until 2011 when the program ended
due to suspension of funding by New Mexico Department of Health. By 2011, 23
pharmacy stores across New Mexico had participated in the program for at least
1 year and 1486 smokers had received the service. Patients were either selfreferred, or approached and invited to participate the program by pharmacists.
The program provided patients with pharmacotherapy up to the value of $137.50
and/or free counseling sessions with pharmacists. No financial compensation
was given to patients for their participation. Participating pharmacists were
reimbursed for providing the service and the program received funding from New
Mexico Tobacco Use Prevention and Control Program (TUPAC). Intake and
follow-up questionnaires developed by TUPAC were adopted and administered
by pharmacists. The intake questionnaire was administered to each patient at
recruitment to obtain baseline information on tobacco use, previous quit attempts,
working and home environment, confidence to quit, importance to quit, and other
demographic characteristics. Three follow-ups at 1 month, 3 months, and 6
months were scheduled to follow up with patients’ tobacco use status. The
follow-ups were either conducted face-to-face in pharmacy or via telephone.
Participants who responded to at least one of the 4 questionnaires (1 intake and
3 follow-ups) were included for analysis.
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Quit rates
For each follow-up, an overall point prevalence quit rate as well as point
prevalence quit rates by year and by pharmacy store were calculated. The
question “do you currently use tobacco products?” was used to determine
participants’ tobacco use status. This question only measured patients’ tobacco
use status at the moment of the follow-up. “Intention to treat” was adopted for
calculating quit rates. Specifically, missing at follow-ups was assumed to be
failures and included in the quit rate calculation.
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Survival Analysis
In addition to calculating point prevalence quit rates, Kaplan-Meier survival
curves were used to present the probability of a participant remaining
continuously abstinent over time until the final follow-up. Cox proportional hazard
model was used as the multivariate analysis to assess what patient
characteristics were associated with relapse. The question “have you used
tobacco even once since your quit date?” was asked at each follow-up and it was
used to determine patients’ continuous abstinence status. At the 3 months and 6
months follow-up, a question “how long did you remain quit” was asked if patients
reported that they had used tobacco since quit date. Together with the intake and
follow-up dates, these two questions were used to determine how long a
participant remained abstinent after their quit date. Figure 1 demonstrates how
the time of abstinence was assigned to each individual.
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Figure 1 Schematic for Assigning Time of Abstinence

Duration1 not missing------t=minimum (LQUIT3M, duration1)
LQUIT3M not missing
Failed

Duration1 missing----------t=minimum (LQUIT3M, 90 days)

Duration1 not missing------t=minimum (LQUIT6M, duration1)
LQUIT6M not missing
Duration1 missing-----t=minimum (LQUIT6M, 90 days)
LQUIT3M missing
Duration1 not missing------t=duration1/2

LQUIT6M missing
Duration1 missing------t=15 days
USETOB1M

Quit

Missing

USETOB3M……

USETOB3M……

*USETOB1M: patients’ response to ever used tobacco since quit date at 1 month follow-up
USETOB3M: patients’ response to ever used tobacco since quit date at 3 months follow-up
LQUIT3M/LQUIT6M: if reported failure to quit at 3 months follow-up, how long the patient remained quit
Duration1: time period between intake and 1 month follow-up
t: assigned time of abstinence
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Quitting patterns and transitions
One of the primary goals of the study was to characterize patients with quitting
patterns. We defined 4 distinctive quitting patterns, which made quitting pattern a
polytomous outcome. Therefore, multinomial logistic regression model was used
to identify patients’ characteristics for each quitting pattern. Patients were
categorized in two ways. In both categorizations, we only considered patients’
abstinent status at the point of follow-up, determined by the question “do you
currently use tobacco?” Missing at any follow-up was considered as failure to quit.
Patients were first categorized into 4 groups: immediate quitters (IQ), delayed
quitters (DQ), once quitters (OQ), and never quitters (NQ). IQ were those who
achieved initial abstinence immediately at 1 month and remained abstinent at the
other two follow-ups. DQ were those who did not successfully quit using tobacco
at 1 month or both 1 month and 3 months, but eventually succeeded at 6 months.
The term OQ was used to characterize those who quit smoking at 1 month or 3
months, but did not achieve final success at 6 months. NQ were those who failed
to be abstinent at any of the 3 follow-ups. The patients were also categorized by
their transition of tobacco use behaviors. Their transitions could be classified as
no transition, forward transition, backward transition, or fluctuation. Staying
abstinence or using tobacco across 3 follow-ups was defined as no transition.
Moving from smoking to abstinence only once during 3 follow-ups was forward
transition while the opposite was backward transition. Transiting between
abstinence and smoking twice was considered as fluctuation (Figure 2).
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Figure 2 Categorization of Patients Based on Quitting Pattern and Transition
Figure 1 Descrtion of Quitting Patterns
Month 3
Month 1
Intake
follow-up
follow-up

Month 6
follow-up
Successful

Successful
Successful

Immediate quitters, no transition
Unsuccessful
Once quitters, backward transition

Unsuccessful
All
participants

Successful
Delayed quitters, fluctuation
Unsuccessful

Successful

Once quitters, backward transition

Successful
Delayed quitters, forward transition
Unsuccessful

Unsuccessful

Once quitters, fluctuation

Unsuccessful

Successful
Delayed quitters, forward transition

Unsuccessful
Never quitters, no transition
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From our literature review, we did not find any studies that assessed the
relationships between quitting patterns and smokers’ characteristics.
Nevertheless, there has been abundant literature discussing predictors of
successful quitters. The defined quitting patterns could be seen as a further
categorization of successfully quitters and non-quitters. Those who succeeded at
6 months were further classified as IQ and DQ, whereas those who failed in the
end were categorized into OQ and NQ. Therefore, the literature on predictors of
successful quitters should be, to some extent, relevant to patients’ quitting
patterns. We decided to fit the predictors of successful quitters identified from the
literature into our multinomial logistic regression model of quitting patterns.
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Elements of an effective tobacco cessation program
In order to understand what makes an effective tobacco cessation program and
how a program impacts patients’ quitting behaviors, we conducted a case study
with pharmacists who participated in providing the program. Pharmacists who
provided the tobacco cessation service to at least 25 patients were contacted
and invited to participate in a 20 minutes interview. The interview was
administered face-to-face or over phone by one of the investigators. All the
responses were collected anonymously.

As suggested by the literature, settings where interventions are delivered are
associated with intervention effectiveness. Therefore, we asked 3 questions
regarding the size and type of the pharmacy. The rest of the questions were
related to the service, containing 3 dimensions with respective focus on following
up with patients, counseling, and pharmacists’ perception about the program. We
integrated aspects of contents, duration, frequency, and format into the questions
about follow-ups and counseling. Four questions about pharmacists’ perceptions
of the tobacco cessation service they provided in the end of the survey (Appendix
B). Pharmacists’ responses were summarized and assessed in a qualitative
manner. We were particularly interested in the reasons why some pharmacists
were more successful than others and how their practice differed.
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Data cleaning and re-categorization
Often, the follow-ups did not take place exactly at 1 month, 3 months, and 6
months. We set a time range that we believed was plausible for each follow-up.
Dates of follow-ups outside the time range were considered erroneous and were
changed to missing. For 1 month follow-up, a visit occurred between 10 days to
90 days after intake was believed to be reasonable. The range for 3 months and
6 months follow-up were set as 30-270 days and 60-540 days, respectively.
When patients’ response to their continuous abstinence status (“have you used
tobacco even once since your quit date?”) at later follow-ups contradicted with
their response at earlier follow-ups, we assumed the earlier response to be more
accurate and used it to calculate length of abstinence.

We re-categorized age, education, number of cigarettes consumed per day,
tobacco use in the past 30 days, pharmacotherapy use, importance to quit,
confidence to quit, and number of class sessions attended based on percentile
distribution. Both confidence to quit and importance to quit were measured on a
scale of 1 to 5 with 5 being the most confident/important. Confidence to quit was
divided into score less than 3, equal to 3, equal to 4, and equal to 5. Importance
to quit was divided into score equal to 3 or less, equal to 4, and equal to 5. Age
was categorized into less than 18 years, 18 to 34 years, 35 to 44 years, 45 to 54
years, 55 to 64 years, and 65 years or older. Education was re-classified as
eighth grade or less, some high school or high school, some college or above.
Tobacco use in the past 30 days consisted of 3 groups: “only cigarettes”,

36

“cigarettes, bidis, chew/dip”, and “other combinations”. Use of pharmacotherapy
was classified as none, only NRT, only varenicline, and other combinations.
Number of class sessions attended was classified into one session, two sessions,
and three sessions or more. We incorporated questions about whether a patient
attempted to quit in the past year and how long the patient remained quit at that
attempt into one variable, namely “quit attempt in the past year”. It consisted of 5
groups: “didn’t try at all”, “tried and stayed quit for 1 week or less”, “tried and
stayed quit for 1 week-1 month”, “tried and stayed quit for 1 month-6 months”,
and “tried and stayed quit for more than 6 months”. For the rest of the variables,
we kept the original categorization from the intake questionnaire. Whether used
alternative method to quit, and gender were binary. Workplace ban of smoking
had 3 options: “yes”, “no”, and “I don’t work”. Home ban of smoking contained 4
groups, which were “yes, anywhere”, “only in certain rooms & outdoors”, “only
outdoors”, and “no, not allowed at all”. Presence of other tobacco users in the
household had 3 groups including “no other tobacco users”, “someone smokes”,
and “someone uses smokeless tobacco”. A likert scale was used to measure
patients’ satisfaction about the program including options “very satisfied”,
“satisfied”, “somewhat satisfied”, and “not satisfied”.

Although Fagerstrom Test for Nicotine Dependence (FTND) was not given to
patients, the baseline questionnaire adopted two questions from FTND. One was
“how many cigarettes/day do you smoke?”, and the other one was “how soon
after you wake up do you smoke your first cigarette?”. Number of cigarettes per
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day was divided into 4 groups: half pack per day or less, half pack to 1 pack, 1
pack to 1.5 packs, and more than 1.5 packs. Time to first use of tobacco after
waking also had 4 groups including “within 5 minutes”, “6-30 minutes”, “31-60
minutes”, and “after 60 minutes”. A modified FTND was created using these 2
pieces of information, with possible scores ranging from 0 to 6. The same scoring
scheme from FTND was used and the 2 individual item scores were summed up
to obtain a total modified FTND score for each patient in the sample. Patients
were grouped based on their modified FTND score (groups: score 0-2, score 3,
score 4, and score 5-6). Higher score indicated higher nicotine dependence.
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Statistical analyses
Statistical analyses performed are summarized in Table 2. An alpha level of 0.05
was adopted for all the statistical analyses in this study. SAS 9.2 was used to
conduct all the statistical analyses.

1) Quit rates
Chi-square tests were used to compare the quit rates by year and by
pharmacy store.

2) Survival analysis
Kaplan Meier survival function is provided below. To apply it to our case, it
is a product of the proportion of patients who remain quit at t 1, t2, … , ti,
where ni is the number of people at risk of relapse (excluding those who
were already censored or relapsed) just prior to ti and di is the number of
people who relapse during t i and ti+1. Patients who stayed quit throughout
the program period were censored. Their length of continuous abstinence
was defined as the duration between the day of the last follow-up and the
day of intake. We also censored those who were lost to follow-up but did
not relapse during the period when they were under observation. Log rank
test was used for univariate analysis to compare abstinence experience
between patients with different baseline characteristics.
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Table 2 Statistical Tests Performed
Objective/analysis
Compare quit rates
across pharmacies
and years
Survival analysis
Pattern analysis

Univariate
statistical tests
Chi-square test

Multivariate
statistical tests
NA

Multivariate model
building
NA

Log-rank test

Cox proportional
hazard model
Multinomial logistic
regression

1) Enter any
variable with pvalue<0.05 in the
univariate analysis;
2)Backward
elimination using
LR test

Multinomial logistic
regression
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Variables with p-value less than 0.05 from log-rank test were included in
the Cox proportional hazard model. The hazard function is also provided.
It measures the hazard of relapsing at time t given a specified set of
patient characteristics X. Hazard ratio (HR), which compares the hazard of
relapse between two groups with different characteristics, is calculated by
dividing the hazard of one group by the other. However, the assumption of
proportionality needs to be met in order for Cox proportional hazard model
to yield unbiased estimates of HR. The model assumes that the relative
hazard of relapse is independent of time. In other words, the relative
hazard of one group relapsing compared to another group needs to be
constant over time, otherwise the estimated HR would be biased. A
hazard rate that is increasing over time tends to overestimate the impact
of the independent variable, whereas a hazard rate that is decreasing over
time tends to bias the HR to zero.96

h(t)=h0(t) exp(

1x1+

2x2+

…+

ixi)

Hazard Ratio= h(t)p/h(t)q

Use of pharmacotherapy, tobacco use, number of cigarettes consumed
per day, time to first use of tobacco after waking, quit attempt in the past
year and duration of abstinence, confidence to quit, importance to quit,
home ban of smoking, presence of other smokers in household, workplace
ban of smoking, age, gender, and education were considered as potential
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factors that could impact patients’ abstinence and were included in the
analyses.

3) Quitting patterns
Multinomial logistic regression was performed as both univariate and
multivariate analysis for characterizing quitting patterns. Based on the
findings from the literature review on predictors of successful quitting,
baseline characteristics obtained from the intake questionnaire including
use of pharmacotherapy, quit attempt in the past year and duration of
abstinence, confidence to quit, importance to quit, home ban of smoking,
presence of other smokers in household, workplace ban of smoking, age,
gender, and education were examined in the multinomial logistic
regression model. The modified FTND score was also included. Although
tobacco use was not identified as a predictor of successful quitting in the
existing literature, we believed that it might also be related to one’s risk of
relapse and quitting pattern and decided to include it in the analyses.

All the variables were examined separately in univariate analysis first. Any
variable with a global p value less than 0.05 was included in multivariate
analysis. Backward elimination strategy was adopted for multivariate
analysis. Variables that were not significant were tested individually in
descending order of p value for their importance to the model. The
likelihood ratio (LR) test was used to compare the full model (with the
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variable being tested) and the reduced model (without the variable being
tested). If LR test was significant, it meant that the variable was important
in terms of explaining the variation in quitting patterns observed among
patients. Therefore, the decision to keep a variable in the model was
made based on whether the LR test was significant. Information on
income, ban of smoking at workplace, alternative method to quit, number
of class sessions attended, and satisfaction about the program were only
collected for year 2004-2007. In order to maintain more sample size and
therefore statistical power, we decided not to include these four variables
in the multivariate analysis.

43

Informed consent
The existing database was already de-identified. The pharmacists who
participated in the interview were consented. The study was approved by the
Human Research Protection Office at the University of New Mexico.
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Chapter 4 Results
After excluding patients who failed to respond to any of the four interviews, 1486
patients were included for analysis. Table 3 shows the baseline characteristics of
the study sample. About 90% of them were between 18 to 64 years old at the
time of recruitment. There were fewer male patients than female patients (44.5%
vs. 55.5%), among whom 15 (2%) of them were pregnant at baseline. The
majority of them were white (70.6%). Almost 47% had at least some college
education and 63.7% of them reported they did not have health insurance.
Regarding tobacco use in the past 30 days, except that 53.7% of the patients
only smoked cigarettes, a large proportion of them (37.4%) reported using
cigarettes, pipes, and chew/dips (all three of them). Among those who smoked
cigarettes, more than 20% of them consumed more than 1 pack of cigarettes per
day. From the reimbursement invoices obtained from NMPCF, we found that
18.9% of the patients attempted to quit without aid of pharmacotherapy, 41.5%
only used NRT, and 34.5% only used varenicline. The patients seemed to have a
high level of nicotine dependence with 44.3% of them reporting having their first
cigarette within 5 minutes after wake up. Almost 20% of the patients had a
modified FTND score of 5 or 6, indicating a relatively high level of nicotine
dependence. More than 70% of the patients had tried to quit in the preceding
year. Nearly half of them reported no workplace ban of tobacco use and 46.3% of
them were allowed to smoke anywhere at home. A little more than half of the
patients did not have anyone else who was tobacco user in their household at
the time of baseline interview. Most the patients indicated the importance for
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them to quit (81.3% scored 5 on the scale), but almost half of the patients’
reported their confidence to quit was 3 or less on a scale of 5. More than 70% of
the patients reported that they had attempted to quit in the past year. For the
years in which use of alternative methods to quit, number of sessions attended,
and participants’ satisfaction were collected, 80.7% patients did not use any
alternative method to help themselves to quit, the majority attended at least one
session or class, and more than half of them were very satisfied with the service
at 1 month.
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Table 3 Characteristics of Included Participants from NMPCF Tobacco Cessation Program
Characteristics
Age
<18 years
18-34 years
35-44 years
45-54 years
55-64 years
>=65 years
>-65

N (%)
49 (3.6%)
312 (22.6%)
295 (21.4%)
374 (27.1%)
263 (19.0%)
89 (6.4%)

Gender
Male
Female
Pregnant

606 (44.5%)
755 (55.5%)
15 (2%)

Ethnicity
White
Hispanic
Other

961 (70.6%)
324 (23.8%)
77 (5.6%)

Education level
Eighth grade or less
Some high school or high school
Some college or college or college above

58 (4.3%)
652 (48.7%)
628 (46.9%)

Annual household income*
Less than $10,000
$10,000---$19,999
$20,000---$49,999
$50,000—$74,999
$75,000 or more

81 (18.0%)
90 (20.0%)
212 (47.0%)
46 (10.2%)
22 (4.9%)

Health insurance
Yes
No

454 (36.3%)
797 (63.7%)

Use tobacco everyday
Yes
No

1325 (96.4%)
50 (3.6%)
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Table 3 cont.
Characteristics
Tobacco use pattern in the past 30 days
Only cigarettes
Only one type of tobacco (not cigarettes)
Cigarettes and pipes
Cigarettes and chew/dips
Cigarettes, pipes, and chew/dips
Cigarettes, pipes, and bidis
Other combinations

N (%)
741 (53.7%)
25 (1.8%)
21 (1.5%)
27 (2.0%)
516 (37.4%)
21 (1.5%)
29(2.1%)

# of cigarettes consumed per day
<=half pack
>half pack, but <=1 pack
>1 pack, but <=1.5 packs
>1.5 packs

338 (27.1%)
631 (50.5%)
185 (14.8%)
95 (7.6%)

Time to first use of tobacco after wake up
Within 5 minutes
6 to 30 minutes
31-60 minutes
After 60 minutes

606 (44.3%)
473 (34.6%)
188 (13.7%)
102 (7.5%)

Modified Fagerstrom score (maximum
possible=6)
0-2
3
4
5-6

339 (27.4%)
358 (28.9%)
347 (28.1%)
193 (15.6%)

Pharmacotherapy used
None
Only NRT
Only varenicline
Only bupropion
NRT and bupropion
Other combinations

256 (18.9%)
561 (41.5%)
467 (34.5%)
38 (2.8%)
26 (1.9%)
5 (0.4%)

Ban of tobacco use at workplace/school*
Yes
No
I don’t know
I don’t work

295 (29.7%)
496 (49.9%)
30 (3.0%)
173 (17.4%)
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Table 3 cont.
Characteristics
Quit attempt in the past year
Didn’t try at all
Tried and stayed quit for <=1 week
Tried and stayed quit for >1 week, but<= 1
month

N (%)
366 (28.4%)
100 (7.8%)
378 (29.3%)

Tried and stayed quit for > 1 month, but <=6
months

203 (15.8%)

Tried and stayed quit for > 6 months

242 (18.8%)

Allowing smoking at home
Yes, anywhere
Only in certain rooms & outdoors
Outdoors only
No, not allowed at all

633 (46.3%)
175 (12.8%)
389 (28.4%)
171 (12.5%)

Others use tobacco in the household
Yes, someone who smokes
Yes, someone who uses smokeless tobacco
No

586 (42.9%)
36 (2.6%)
744 (54.5%)

Confidence to quit (scale 1-5)
<3
3
4
5

223 (16.3%)
357 (26.0%)
367 (26.8%)
425 (31.0%)

Importance to quit (scale 1-5)
<=3
4
5

53 (5.5%)
181 (13.1%)
1120 (81.3%)

Used alternate method (eg. acupuncture)*
Yes
No

113 (19.3%)
472 (80.7%)

# of sessions attended*
0
1
2
>=3

53 (9.5%)
275 (49.5%)
100(18.0%)
128(23.0%)
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Table 3 cont.
Characteristics
Satisfaction about the program at 1 month*
Not at all satisfied
Somewhat satisfied
Satisfied
Very satisfied
*information only collected from 2004 to 2007

N (%)
4 (0.7%)
40 (7.0%)
205 (35.9%)
322 (56.4%)
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Quit rates
The overall point prevalence quit rate was 30.2%, 20.3%, and 18.7% at 1 month,
3 months, and 6 months, respectively. Point prevalence quit rates by year and by
pharmacy were calculated and presented in Figures 3 and 4. The chi-square
tests showed that the quit rates were significantly different both across years and
across pharmacies at all three follow-ups (p<0.0001). Year 2009 had the highest
6-month quit rate (28.5%). Year 2004 and 2010 achieved a 6-month quit rate
greater than 20%. The quit rate varied more dramatically by pharmacy with
pharmacy 8 having the highest 6-month quit rate of 59.4%.
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Figure 3 Point Prevalence Quit Rates by Year
45.0%
40.0%
35.0%
28.5%

30.0%

26.4%

25.0%
20.5%
18.5%

20.0%
15.0%

15.1%

14.4%
9.7%

10.0%
5.0%

0.0%
Year 2004 (n=190) Year 2005 (n=208) Year 2006 (n=227) Year 2007 (n=238) Year 2008 (n=220) Year 2009 (n=193) Year 2010 (n=208)
Quit rate at 1 mo

Quit rate at 3 mo
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Quit rate at 6 mo

Figure 4 Point Prevalence Quit Rates by Pharmacy
80.0%
70.0%
59.4%
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40.0%
30.0%
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10.0%

2.9%

6.7%
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0.1%

0.0%
Pharmacy 1 Pharmacy 2 Pharmacy 3 Pharmacy 5 Pharmacy 7 Pharmacy 8 Pharmacy 9 Pharmacy Pharmacy Pharmacy Pharmacy
(n=518)
(n=165)
(n=44)
(n=34)
(n=264)
(n=170)
(n=25)
10 (n=25) 13 (n=34) 15 (n=39) 16 (n=89)
Quit rate at 1 mo

Quit rate at 3 mo

*Only pharmacies with n≥25 are displayed; mo: month(s)
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Quit rate at 6 mo

Survival analysis
Among the 1486 patients included in the survival analysis, 684 of them were
censored. The majority of them (branch 54, n=456) were censored at the
beginning of observation and we assigned zero day to them as their time of
abstinence (Table 4). The rest (802 patients) relapsed during observation. The
probability of a patient being continuously abstinent for 7 days was 89.1%, while
the likelihood of being abstinent for 30 days and 180 days was 46.0% and 16.5%,
respectively. A dramatic decrease in probability of remaining quit occurred in the
first two weeks, dropping to 77.3%. The mean abstinent time of the study sample
was 76.81 days (standard error= 3.59 days). This mean time is likely to be an
underestimate due to the fact that a large number of patients were censored. The
Kaplan-Meier survival curve of the study sample is displayed in Figure 5.
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Table 4 Assignment of Time of Abstinence
Branch
Inference of t
USETOB1M=fail
1
LQUIT3M not missing, d1 not missing
2
LQUIT3M not missing, d1 missing
3
LQUIT3M missing, LQUIT6M not missing, d1 not missing
4
LQUIT3M missing, LQUIT6M not missing, d1 missing
5
LQUIT3M missing, LQUIT6M missing, d1 not missing
6
LQUIT3M missing, LQUIT6M missing, d1 missing
USETOB1M=quit, USETOB3M=failed
7
LQUIT3M not missing, d1>=LQUIT3M
8
LQUIT3M not missing, d1<LQUIT3M, d2 not missing
9
LQUIT3M not missing, d1<LQUIT3M, d2 missing
10
LQUIT3M missing, LQUIT6M not missing, d1>=LQUIT6M
11
LQUIT3M missing, LQUIT6M not missing, d1<LQUIT6M, d2 not missing
12
LQUIT3M missing, LQUIT6M not missing, d1<LQUIT6M, d2 missing
13
LQUIT3M missing, LQUIT6M missing, d2 not missing
14
LQUIT3M missing, LQUIT6M missing, d2 missing
USETOB1M=quit, USETOB3M=quit, USETOB6M=failed
15
LQUIT6M not missing, d2>=LQUIT6M
16
LQUIT6M not missing, d2<LQUIT6M, d3 not missing
17
LQUIT6M not missing, d2<LQUIT6M, d3 missing
18
LQUIT6M missing, d3 not missing
19
LQUIT6M missing, d3 missing
USETOB1M=quit, USETOB3M=quit, USETOB6M=quit (censored)
20
d3 not missing
21
d3 missing
USETOB1M=quit, USETOB3M=quit, USETOB6M=missing (censored)
22
d2 not missing
23
d2 missing
USETOB1M=quit, USETOB3M=missing, USETOB6M=failed
24
LQUIT6M not missing, d1>=LQUIT6M
25
LQUIT6M not missing, d1<LQUIT6M, d3 not missing
26
LQUIT6M not missing, d1<LQUIT6M, d3 missing
27
LQUIT6M missing, d3 not missing
28
LQUIT6M missing, d3 missing

55

t
Min(LQUIT3M, d1)
Min(LQUIT3M, 90)
Min(LQUIT6M, d1)
Min(LQUIT6M, 90)
d1/2
15 days
d1
Min(LQUIT3M, d2)
Min(LQUIT3M, 270)
d1
Min(LQUIT6M, d2)
Min(LQUIT6M, 270)
d2/2
45 days
d2
Min(LQUIT6M, d3)
Min(LQUIT6M, 540)
d3/2
90 days
d3
180 days
d2
90 days
d1
Min(LQUIT6M, d3)
Min(LQUIT6M, 540)
d3/2
90 days

N (%)
585 (39.4%)
105 (7.1%)
92 (6.2%)
16 (1.1%)
16 (1.1%)
155 (10.4%)
201 (13.5%)
75 (5.0%)
9 (0.6%)
36 (2.4%)
2 (0.1%)
2 (0.1%)
2 (0.1%)
0 (0.0%)
0 (0.0%)
24 (1.6%)
14 (0.9%)
0 (0.0%)
5 (0.3%)
0 (0.0%)
9 (0.6%)
0 (0.0%)
70 (4.7%)
61 (4.1%)
9 (0.6%)
38 (2.6%)
35 (2.4%)
3 (0.2%)
14 (0.9%)
2 (0.1%)
5 (0.3%)
0 (0.0%)
6 (0.4%)
1 (0.1%)

USETOB1M=quit, USETOB3M=missing, USETOB6M=quit (censored)
29
d3 not missing
30
d3 missing
USETOB1M=quit, USETOB3M=missing, USETOB6M=missing (censored)
31
d1 not missing
32
d1 missing
USETOB1M=missing, USETOB3M=failed
33
LQUIT3M not missing, d2 not missing
34
LQUIT3M not missing, d2 missing
35
LQUIT3M missing, LQUIT6M not missing, d2 not missing
36
LQUIT3M missing, LQUIT6M not missing, d2 missing
37
LQUIT3M missing, LQUIT6M missing, d2 not missing
38
LQUIT3M missing, LQUIT6M missing, d2 missing
USETOB1M=missing, USETOB3M=quit, USETOB6M=failed
39
LQUIT6M not missing, d2>=LQUIT6M
40
LQUIT6M not missing, d2<LQUIT6M, d3 not missing
41
LQUIT6M not missing, d2<LQUIT6M, d3 missing
42
LQUIT6M missing, d3 not missing
43
LQUIT6M missing, d3 missing
USETOB1M=missing, USETOB3M=quit, USETOB6M=quit (censored)
44
d3 not missing
45
d3 missing
USETOB1M=missing, USETOB3M=quit, USETOB6M=missing (censored)
46
d2 not missing
47
d2 missing
USETOB1M=missing, USETOB3M=missing, USETOB6M=failed
48
LQUIT6M not missing, d3 not missing
49
LQUIT6M not missing, d3 missing
50
LQUIT6M missing, d3 not missing
51
LQUIT6M missing, d3 missing
USETOB1M=missing, USETOB3M=missing, USETOB6M=quit (censored)
52
d3 not missing
53
d3 missing
USETOB1M=missing, USETOB3M=missing, USETOB6M=missing (censored)
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All

d3
180 days
d1
30 days
Min(LQUIT3M, d2)
Min(LQUIT3M, 270)
Min(LQUIT6M, d2)
Min(LQUIT6M,270)
d2/2
45 days
d2
Min(LQUIT6M, d3)
Min(LQUIT6M, 540)
d3/2
90 days
d3
180 days
d2
90 days
Min(LQUIT6M, d3)
Min(LQUIT6M, 540)
d3/2
90 days
d3
180 days
0 day

10 (0.7%)
9 (0.6%)
1 (0.1%)
78 (5.3%)
22 (1.5%)
56 (3.8%)
73 (4.9%)
37 (2.5%)
9 (0.6%)
4 (0.3%)
0 (0.0%)
13 (0.9%)
10 (0.7%)
5 (0.4%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
4 (0.3%)
1 (0.1%)
4 (0.3%)
4 (0.3%)
0 (0.0%)
12 (0.8%)
9 (0.6%)
3 (0.2%)
36 (2.4%)
18 (1.2%)
10(0.7%)
6 (0.4%)
2 (0.1%)
16 (1.0%)
11 (0.7%)
5 (0.3%)
456 (30.7%)
456 (30.7%)

*USETOB: ever used tobacco since quit date; LQUIT: reported time of abstinence, d: duration between follow-ups and intake; Min: minimum
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Figure 5 Kaplan-Meier Survival Curve----All Patients (n=1486)
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Censored Observations

400

500

Log rank test was performed to determine patient characteristics that influenced
patients’ probability of remaining quit and their abstinence experience. Except
income, work environment, alternative method used to quit, class sessions
attended, and satisfaction about the program, all the other baseline
characteristics listed in table 1 were analyzed individually. The results of log rank
tests are presented in Table 5. Age, pharmacotherapy, and tobacco use in the
past 30 days were found to be significantly associated with patients’ likelihood of
remaining continuously abstinent. Patients under 18 years old had a better
chance of keeping themselves from using tobacco again compared to all the
other age groups (Figure 6). The p-value for the log rank test was 0.03. Their
likelihood of staying abstinent for 120 days was 32.4%. Figure 7 shows the
survival curve for each pharmacotherapy group. Log rank test indicated that the
quitting experiences by pharmacotherapy groups were significantly different
(p=0.02). Patients who only used varenicline had the best quitting experience in
the whole time. Their likelihood of quitting continuously for 120 days was 22.9%.
Patients who only used NRT had higher likelihood of remaining quit than those
who did not use pharmacotherapy and those who tried several types of
pharmacotherapy in the first 4 months. Patients who only used NRT had a
probability of 18.3% to be continuously abstinence for 120 days and the
probability for 180 days was 14.7%. The likelihood of continuous abstinence for
the first 30 days was similar among patients with different tobacco use patterns
with a rate around 40%. Starting from 30 days, patients who used cigarettes,
pipes, and chew/dip in the past 30 days had better quitting experience than
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others. Their probability of remaining quit at day 120 was 21.4%, whereas the
probability for those who only smoked cigarettes in the past month was 16.6%
(Figure 8).
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Table 5

Kaplan-Meier Survival Analysis---Results of Log Rank Tests

Variable
Age
Gender
Ethnicity
Education level
Health plan coverage
Use tobacco everyday
Tobacco use pattern in the past 30 days
# of cigarettes per day
Time to first use of tobacco after wake up
Pharmacotherapy used
Quit attempt in the past year
Allowing smoking at home
Presence of other tobacco user in the household
Confidence to quit
Importance to quit
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p-value of log-rank test
0.03
0.83
0.69
0.06
0.08
0.14
0.03
0.27
0.36
0.02
0.06
0.59
0.88
0.41
0.19

Figure 6 Kaplan-Meier Survival Curve by Age Group (n=1382)
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agecat=35-44 years
agecat=55-64 years
agecat=>=65 years

Censored agecat=35-44 years
Censored agecat=55-64 years
Censored agecat=>=65 years

Figure 7 Kaplan-Meier Survival Curve by Pharmacotherapy (n=1353)
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Figure 8 Kaplan-Meier Survival Curve by Tobacco Use in the Past 30 Days (n=1380)
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When we entered the covariates that were significant in the Kaplan-Meier
survival analysis into the Cox proportional hazard model, we found that the HRs
for the covariates were dependent on time. Since the assumption of
proportionality was violated, we decided not to use the Cox proportional hazard
model and kept the analysis in the univariate level. For the sake of demonstrating
the violation, we presented the results of Cox proportional hazard model in Table
6 and Table 7. The interactions between time of abstinence and age group,
tobacco use in the past 30 days, and pharmacotherapy used were significant
(Table 7). The coefficients of the interactions were negative, which indicated that
the hazard rate decreased over time. Also, the overall test of proportionality was
also significant with a p-value less than 0.0001. This indicated the dependence of
hazard ratios on time. When excluding the interactions with time of abstinence,
the hazard ratios were biased toward the null, which was exactly as Menard et al
described 96 (Table 6). Due to the violation of the assumption of proportionality,
the HR estimates in Table 6 were biased and should not be used.
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Table 6 Multivariate Analysis----Results of Cox Proportional Hazard Model (excluding
interactions with time )
Independent variable
Hazard ratio
p-value
Age
<18 years
0.59
0.02
18-34 years
referent
--------35-44 years
1.07
0.58
45-54 years
1.06
0.58
55-64 years
1.02
0.89
>=65 years
1.04
0.83
Tobacco use pattern in the past 30
days
Only cigarettes
1.03
0.86
Cigarettes, pipes, and chew/dips
0.94
0.65
Other
referent
---------Pharmacotherapy used
None
referent
---------Only NRT
0.98
0.88
Only varenicline
0.84
0.13
Other
1.06
0.76
*The hazard ratios in Table 6 are biased and should not be used.
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Table 7 Multivariate Analysis----Results of Cox Proportional Hazard Model (including
interactions with time )
Independent variable
Age
<18 years
18-34 years
35-44 years
45-54 years
55-64 years
>=65 years
<18 years*log(t)
35-44 years*log(t)
45-54 years*log(t)
55-64 years*log(t)
>=65 years*log(t)
Tobacco use pattern in the past 30 days
Other
Only cigarettes
Cigarettes, pipes, and chew/dips
Only cigarettes*log(t)
Cigarettes, pipes, and chew/dips*log(t)
Pharmacotherapy used
None
Only NRT
Only varenicline
Other
Only NRT*log(t)
Only varenicline*log(t)
Other*log(t)
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coefficient

Hazard ratio

p-value

2.41
referent
2.01
2.02
1.99
2.30
-0.75
-0.57
-0.60
-0.54
-0.71

11.16
--------7.44
7.54
7.29
9.94
0.47
0.57
0.55
0.58
0.49

0.002
----------------<0.0001
<0.0001
<0.0001
0.0003
<0.0001
<0.0001
<0.0001
<0.0001

referent
11.52
11.10
-3.11
-3.00

--------101004.20
66027.93
0.04
0.05

--------<0.0001
<0.0001
<0.0001
<0.0001

referent
4.13
4.58
0.73
-1.32
-1.46
-0.22

---------61.91
97.13
2.08
0.27
0.23
0.80

---------<0.0001
<0.0001
0.11
<0.0001
<0.0001
0.14

Quitting pattern analysis
Based on our definition of quitting patterns, the study sample consisted of 162
(10.9%) immediate quitters, 112 (7.8%) delayed quitters, 312 (21%) once quitters,
and 896 (60.3%) never quitters. As for their transitions of tobacco use behaviors
during the program period, 89 (6.0%) moved forward from using tobacco to
abstinence, 259 (17.4%) had a backward transition, 80 (5.4%) patients’
abstinence status fluctuated, and 1058 (71.2%) patients had the same status,
staying quit or using tobacco, at all three follow-ups (Table 8).
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Table 8 Quitting Patterns and Transitions of Included Participants from NMPCF Tobacco
Cessation Program
Quitting patterns
Immediate quitters
Delayed quitters
Once quitters
Never quitters

162 (10.9%)
116 (7.81%)
312 (21.00%)
896 (60.30%)

Quitting transitions
Forward transition
Backward transition
Fluctuation
No transition

89 (5.99%)
259 (17.43%)
80 (5.38%)
1058 (71.20%)

Patterns & transitions
Immediate quitters, no transition
Delayed quitters, forward transition
Delayed quitters, fluctuation
Once quitters, fluctuation
Once quitters, backward transition
Never quitters, no transition

162 (10.90%)
89 (5.99%)
27 (1.82%)
53 (3.57%)
259 (17.43%)
896 (60.30%)
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The results of the univariate multinomial logistic regressions are presented in
Table 9. Compared to patients with age between 18 to 34, patient under 18 years
old were 5.27 time more likely to be IQ and 3.21 times more likely to be OQ.
Males were 1.65 times more likely to be DQ than females. Hispanics were more
likely to be IQ compared to others (OR=1.68, 95% CI:1.15-2.45). Education was
inversely related to one’s probability of quitting. Patients who used tobacco
everyday were less likely to be DQ and OQ compared to non-daily tobacco users.
Patients who used cigarettes, pipes, and chew/dip in the past 30 days were more
likely to quit than those who only smoked cigarettes. Patients with a modified
FTND score of 4, indicating greater nicotine dependence, were less likely to be
DQ than those with a score between 0 to 2 (OR=0.50, 95% CI: 0.27-0.93).
Compared with those quitting without aid of pharmacotherapy, patients who only
used NRT were more likely to be OQ and patients who only used varenicline
were more likely to be IQ and OQ. It was unexpected that patients who
attempted to quit in the past year were less likely to be successful at the current
attempt than those who did not make attempt to quit in the past year. Ban of
tobacco use at work (referent: ban; OR=2.33, 95% CI: 1.37-3.95) and home ban
of smoking (referent: no ban; OR=0.41, 95% CI: 0.21-0.79) decreased the
probability of quitting immediately. Confidence to quit was associated the
likelihood of being IQ. Using alternative method to quit and attending more class
sessions also helped patients quit. The less the patients were satisfied with the
program, the less likely they were IQ and OQ.
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Table 9 Univariate Analysis---Characteristics of Immediate Quitters, Delayed Quitters, and
Once Quitters compared to Never Quitters
Immediate quitters
vs. Never quitters

Delayed quitters
vs. Never quitters

Once quitters vs.
Never quitters

<18 years

5.27 (2.42, 11.42)

1.91 (0.51, 7.18)

2.31 (1.06, 5.03)

18-34 years
35-44 years
45-54 years
55-64 years
>=65 years
Gender

1
0.65 (0.38, 1.11)
0.88 (0.54, 1.41)
0.64 (0.37, 1.12)
0.65 (0.29, 1.47)

1
1.23 (0.65, 2.32)
1.13 (0.61, 2.09)
1.49 (0.80, 2.80)
1.34 (0.56, 3.22)

1
0.79 (0.53, 1.17)
0.83 (0.57, 1.20)
0.72 (0.47, 1.09)
0.70 (0.38, 1.29)

Female
Male
Ethnicity

1
0.97 (0.69, 1.37)

1
1.65 (1.09, 2.49)

1
0.88 (0.67, 1.16)

White
Hispanic
Other
Education level

1
1.68 (1.15, 2.45)
0.97 (0.43, 2.22)

1
1.37 (0.85, 2.20)
1.88 (0.88, 4.03)

1
1.23 (0.89, 1.70)
1.33 (0.75, 2.36)

Eighth grade or less

2.95 (1.40, 6.20)

2.47 (1.01, 6.07)

1.87 (0.96, 3.64)

Some high school or high
school
Some college or college
or college above
Health insurance

1

1

1

1.07 (0.75, 1.53)

0.98 (0.64, 1.50)

0.80 (0.60, 1.06)

No

1

1

1

Yes
Use tobacco every day

0.96 (0.67, 1.39)

1.14 (0.74, 1.75)

1.08 (0.81, 1.45)

No
yes
Tobacco use pattern in
the past 30 days
Only cigarettes
Cigarettes, pipes, and
chew/dips
Other
Modified Fagerstrom
score
0-2 low dependence
3
4
5-6

1
1.33 (0.39, 4.50)

1
0.32 (0.14, 0.74)

1
0.38 (0.20, 0.73)

1
2.36 (1.64, 3.40)

1
3.00 (1.94, 4.63)

1
2.22 (1.66, 2.96)

1.97 (1.09, 3.56)

1.96 (0.94, 4.11)

1.81 (1.12, 2.91)

1
0.80 (0.51, 1.28)
0.67 (0.42, 1.09)
0.58 (0.32, 1.05)

1
0.92 (0.54, 1.56)
0.50 (0.27, 0.93)

1
0.75 (0.51, 1.10)
0.89 (0.61, 1.29)
0.68 (0.43, 1.07)

Age

0.52 (0.25, 1.06)
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Table 9 Cont.

Quit attempt in the past
year
Didn’t try at all
Tried and stayed quit for
<=1 week
Tried and stayed quit
for >1 week, but<= 1
month
Tried and stayed quit
for > 1 month, but <=6
months
Tried and stayed quit
for > 6 months
Ban of tobacco use at
workplace/school
Yes
No
I don’t work
Allowing smoking at
home
Yes, anywhere
Only in certain rooms &
outdoors
Outdoors only
No, not allowed at all
Presence of other
tobacco users in the
household
Yes, someone who
smokes
Yes, someone who uses
smokeless tobacco
No
Confidence to quit
(scale 1-5)
<3 low
3
4
5
Importance to quit
(scale 1-5)
<=3 low
4
5

Immediate quitters
vs. Never quitters

Delayed quitters
vs. Never quitters

Once quitters vs.
Never quitters

1
0.29 (0.12, 0.71)

1

1

0.62 (0.25, 1.55)

0.83 (0.48, 1.44)

0.56 (0.36, 0.87)

1.04 (0.62, 1.76)

0.70 (0.48, 1.02)

0.61 (0.36, 1.03)

0.95 (0.50, 1.80)

0.84 (0.54, 1.30)

0.40 (0.23, 0.70)

0.62 (0.32, 1.22)

0.91 (0.61, 1.37)

1
2.33 (1.37, 3.95)

1

1

1.64 (0.83, 3.25)

1.05 (0.55, 1.98)
1.13 (0.50, 2.56)

1.33 (0.91, 1.94)
1.44 (0.90, 2.33)

1
0.34 (0.17, 0.68)

1
1.04 (0.56, 1.94)

1
0.70 (0.46, 1.09)

0.81 (0.55, 1.19)
0.41 (0.21, 0.79)

1.02 (0.63, 1.67)
1.27 (0.70, 2.30)

0.77 (0.55, 1.06)
0.78 (0.51, 1.20)

1

1

1

0.85 (0.29, 2.50)

1.38 (0.46, 4.16)

0.10 (0.01, 0.74)

1.18 (0.83, 1.68)

1.34 (0.87, 2.05)

0.92 (0.70, 1.21)

1
2.41 (1.33, 4.37)

1
0.75 (0.40, 1.42)

1
1.03 (0.69, 1.54)

3.19 (1.78, 5.71)
3.62 (2.04, 6.43)

1.25 (0.70, 2.23)
2.19 (1.30, 3.71)

1.44 (0.98, 2.12)
2.09 (1.45, 3.01)

1
1.59 (0.80, 3.16)
1.33 (0.75, 2.36)

1
0.66 (0.28, 1.54)
1.09 (0.60, 1.97)

1
0.50 (0.29, 0.87)

71

0.87 (0.60, 1.26)

Table 9 Cont.

Used alternate method
(eg. acupuncture)*
No
Yes
# of sessions attended*
0
1
2
>=3
Satisfaction about the
program at 1 month*
Very satisfied
Satisfied
Somewhat satisfied
Not at all satisfied

Immediate quitters
vs. Never quitters

Delayed quitters
vs. Never quitters

Once quitters vs.
Never quitters

1
4.44 (2.54, 7.79)

1

1

2.00 (0.87, 4.62)

1.68 (0.99, 2.88)

1
1.62 (0.58, 4.55)
2.31 (0.78, 6.89)
6.89 (2.43, 19.52)

1
1.70 (0.55, 5.28)
0.91 (0.24, 3.52)
1.08 (0.28, 4.18)

1
1.82 (0.93, 3.55)
1.10 (0.51, 2.38)
1.57 (0.73, 3.38)

1
0.23 (0.13, 0.39)
0.03 (0.004, 0.25)

1

1
0.31 (0.20, 0.48)
0.10 (0.04, 0.26)

0.66 (0.33, 1.31)
0.51 (0.16, 1.62)
----

0.34 (0.03, 3.31)
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----

Other than ethnicity, income, health plan coverage, work ban of tobacco use,
whether using alternative methods to quit, class sessions attended, and
satisfaction about the program, all the other characteristics were entered into the
multivariate model. We first built a model without including pharmacy store as an
independent variable and the results of the model are presented in Table 10.

Controlling for all the other variables in the model, age was statistically
associated with quitting pattern. Compared to patients who were 18-34 years old,
patients under 18 were more likely to be IQ (OR=5.71, 95% CI: 1.84-17.69),
while patients with an age between 45 and 54 years (OR=0.58, 95% CI: 0.360.93) or between 55 to 64 years (OR=0.58, 95% CI: 0.34-0.98) were less likely to
be OQ. Patients with an education level of eighth grade or less were more likely
to be IQ and OQ than those who had high school education. Patients who used
cigarettes, pipes, and chew/dips in the past 30 days were more likely to be OQ
compared to cigarettes smokers (OR=1.93, 95% CI: 1.31-2.85). Nicotine
dependence was significantly associated with one’s likelihood of being IQ.
Compared to those who scored 0-2 on the modified FTND, patients who had a
score of 4 were more likely to be IQ and DQ. Pharmacotherapy only helped to a
certain extent. Patients who used NRT (OR=2.27, 95% CI: 1.36-3.80) or
varenicline (OR=2.41, 95% CI: 1.42-4.10) were more likely to be OQ than those
who did not use any form of pharmacotherapy. Home ban of smoking was still
inversely related to the likelihood of successful quitting after adjustment for other
variables. Patients with higher confidence were more likely to quit, while patients
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reported greater importance to quit were less likely to be successful. Although
gender, education level, whether using tobacco daily, time to first use of tobacco
upon wake up, quit attempt in the past year, and presence of other tobacco users
in the household were not significantly associated with quitting pattern, they
played important roles in the model. The LR test was significant for each of them.
Therefore, we decided to keep all of them in the model. The R square of the
model was 0.20.
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Table 10 Multivariate Analysis---Characteristics of Immediate Quitters, Delayed Quitters,
and Once Quitters compared to Never Quitters (pharmacy stores excluded)
Immediate quitters
vs. Never quitters

Delayed quitters
vs. Never quitters

Once quitters vs.
Never quitters

<18 years
18-34 years
35-44 years
45-54 years
55-64 years
>=65 years
Gender

5.71 (1.84, 17.69)
1
0.63 (0.32, 1.21)
1.15 (0.64, 2.07)
0.52 (0.25, 1.08)
0.45 (0.15, 1.37)

2.46 (0.44, 13.89)
1
1.62 (0.74, 3.51)
1.88 (0.90, 3.94)
2.01 (0.93, 4.33)
1.05 (0.30, 3.63)

2.75 (0.95, 7.96)
1
0.75 (0.46, 1.21)
0.58 (0.36, 0.93)
0.58 (0.34, 0.98)

Female

1

1

1

Male
Education level

0.85 (0.54, 1.32)

1.58 (0.97, 2.58)

0.87 (0.62, 1.23)

Eighth grade or less
Some high school or high
school
Some college or college
or college above
Use tobacco every day

4.47 (1.56, 12.84)

2.61 (1.11, 6.14)

1

1.61 (0.47, 5.52)
1

1.25 (0.79, 2.00)

0.93 (0.56, 1.55)

0.87 (0.61, 1.23)

No
Yes
Tobacco use pattern in
the past 30 days
Only cigarettes
Cigarettes, pipes, and
chew/dips
Other
Modified fagerstrom
score
0-2 low dependence
3
4

1
0.71 (0.14, 3.46)

1
0.35 (0.11, 1.13)

1
0.48 (0.19, 1.24)

1
1.45 (0.87, 2.42)

1
2.02 (1.17, 3.50)

1
1.93 (1.31, 2.85)

0.74 (0.28, 1.95)

1.14 (0.39, 3.33)

1.64 (0.84, 3.20)

1
0.64 (0.37, 1.11)
0.49 (0.27, 0.89)

1
0.79 (0.43, 1.44)
0.43 (0.21, 0.87)

1
0.68 (0.44, 1.06)
0.80 (0.51, 1.26)

5-6
Pharmacotherapy used

0.64 (0.32, 1.28)

0.54 (0.24, 1.19)

0.74 (0.43, 1.29)

None
Only NRT
Only varenicline
Other

1
0.77 (0.41, 1.45)
1.73 (0.94, 3.18)
1.55 (0.58, 4.13)

1
1.57 (0.76, 3.23)
1.46 (0.68, 3.10)
1.39 (0.40, 4.84)

1
2.27 (1.36, 3.80)
2.41 (1.42, 4.10)

Age
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0.45 (0.20, 1.01)

1

1.59 (0.61, 4.15)

Table 10 Cont.
Immediate quitters
vs. Never quitters

Delayed quitters
vs. Never quitters

Once quitters vs.
Never quitters

1

1

1

0.35 (0.11, 1.11)

0.89 (0.30, 2.67)

1.44 (0.72, 2.86)

0.84 (0.48, 1.47)

1.29 (0.68, 2.42)

0.76 (0.47, 1.20)

1.03 (0.52, 2.04)

1.04 (0.47, 2.29)

1.24 (0.73, 2.12)

0.54 (0.26, 1.10)

0.68 (0.30, 1.52)

1.27 (0.77, 2.08)

1
0.21 (0.09, 0.53)

1

1

0.92 (0.45, 1.87)

0.62 (0.37, 1.05)

0.58 (0.35, 0.99)

0.66 (0.36, 1.22)

0.54 (0.35, 0.83)

No, not allowed at all
Presence of other
tobacco users in the
household
Yes, someone who
smokes
Yes, someone who uses
smokeless tobacco
No
Confidence to quit
(scale 1-5)
<3 low
3
4
5
Importance to quit
(scale 1-5)
<=3 low

0.28 (0.12, 0.66)

0.60 (0.26, 1.38)

0.58 (0.33, 1.02)

1

1

1

2.18 (0.61, 7.78)

2.08 (0.52, 8.30)

0.20 (0.03, 1.64)

1.39 (0.88, 2.20)

1.11 (0.66, 1.85)

1.16 (0.82, 1.65)

1
2.06 (0.94, 4.55)
2.68 (1.22, 5.89)
3.03 (1.36, 6.77)

1
0.92 (0.40, 2.13)
1.51 (0.68, 3.34)
1.99 (0.92, 4.33)

1
0.98 (0.56, 1.72)
1.60 (0.92, 2.77)
1.79 (1.04, 3.09)

1

1

4
5

0.54 (0.21, 1.39)
0.35 (0.15, 0.82)

0.83 (0.20, 3.52)
1.00 (0.28, 3.60)

1
0.31 (0.13, 0.73)
0.48 (0.24, 0.96)

Quit attempt in the past
year
Didn’t try at all
Tried and stayed quit for
<=1 week
Tried and stayed quit
for >1 week, but<= 1
month
Tried and stayed quit
for > 1 month, but <=6
months
Tried and stayed quit
for > 6 months
Allowing smoking at
home
Yes, anywhere
Only in certain rooms &
outdoors
Outdoors only
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The variation in quit rates across pharmacies might partly due to differences in
patients recruited at each site. In order to rule out patient selection as an
explanation for the varying quit rate among pharmacies, we built another
multivariate multinomial logistic regression model to examine whether the effect
of pharmacy on the probability of quitting would persist after controlling for patient
characteristics. Pharmacies that provided the service to less than 25 patients
were excluded from the analysis, namely pharmacy 4, 6, 11, 12, 14, and 18-23.
Pharmacy 5, 7, and 15 were further excluded due to its extremely low quit rates.
Low quit rates made the number of IQ and DQ very small, which would invalidate
statistical analysis. The results of the model are presented in Table 11. Using
pharmacy 1 as the reference, pharmacy 8 was more successful in terms of
having more IQ, DQ, and OQ and pharmacy 2 and 16 were less successful.
Patients from pharmacy 8 were 18.25 times more likely to be IQ than patients
from pharmacy 1. After adding pharmacy into the model, R square increased to
0.36, meaning that pharmacy together with other variables in the model
explained 36% of the variance in quitting patterns among patients. Quit attempts
in the past year and presence of household smokers became significant, but
confidence and importance to quit, pharmacotherapy use, modified FTND score
were no longer significant. Adding pharmacy did not change the overall effects of
age, education level, tobacco use in the past 30 days, and home ban of smoking.
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Table 11 Multivariate Analysis---Characteristics of Immediate Quitters, Delayed Quitters,
and Once Quitters compared to Never Quitters (pharmacy stores included)
Immediate quitters
vs. Never quitters

Delayed quitters
vs. Never quitters

Once quitters vs.
Never quitters

1
0.15 (0.04, 0.52)

1
0.17 (0.06, 0.46)

1
0.37 (0.20, 0.69)

2.47 (0.78, 7.84)
20.45 (8.70, 48.06)

0.17 (0.02, 1.42)
9.40 (3.74, 23.62)

0.51 (0.15, 1.69)
2.22 (1.03, 4.76)

0.26 (0.03, 2.35)
--0.23 (0.07, 0.77)

0.49 (0.09, 2.53)
1.26 (0.12, 13.30)
0.06 (0.01, 0.46)

0.94 (0.26, 3.37)
0.97 (0.19, 4.95)
0.19 (0.08, 0.44)

<18 years
18-34 years
35-44 years
45-54 years
55-64 years
>=65 years
Gender

7.04 (1.01, 49.3)

7.01 (1.18, 41.59)

1
0.38 (0.17, 0.84)
1.09 (0.55, 2.19)
0.51 (0.22, 1.20)
0.84 (0.22, 3.15)

4.12 (0.40, 42.51)
1
1.25 (0.54, 2.88)
1.96 (0.88, 4.37)
1.95 (0.81, 4.68)
1.92 (0.48, 7.75)

Female
Male
Education level

1
0.93 (0.55, 1.60)

1
1.67 (0.96, 2.92)

1
0.86 (0.57, 1.29)

Eighth grade or less
Some high school or high
school
Some college or college
or college above
Use tobacco every day

3.95 (0.92, 17.00)
1

2.05 (0.43, 9.73)
1

3.55 (1.21, 10.42)

1.67 (0.94, 2.97)

1.51 (0.84, 2.70)

0.95 (0.62, 1.46)

No
Yes
Tobacco use pattern in
the past 30 days
Only cigarettes

1
0.90 (0.16, 5.05)

1
0.42 (0.12, 1.48)

1
0.46 (0.17, 1.28)

1

1

Cigarettes, pipes, and
chew/dips
Other
Modified fagerstrom
score
0-2 low dependence

1.74 (0.89, 3.40)

1.91 (0.995, 3.68)

1
2.54 (1.56, 4.14)

0.84 (0.28, 2.55)

0.87 (0.27, 2.83)

2.08 (0.97, 4.46)

1

1

1

3
4
5-6

1.20 (0.62, 2.33)
0.67 (0.33, 1.37)
0.97 (0.41, 2.31)

1.18 (0.60, 2.31)
0.53 (0.25, 1.14)
0.66 (0.26, 1.69)

0.93 (0.55, 1.58)
0.94 (0.55, 1.60)
0.90 (0.46, 1.76)

Pharmacy store
1
2
3
8
9
13
16
Age
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1
0.64 (0.37, 1.11)
0.60 (0.34, 1.06)
0.57 (0.30, 1.08)
0.47 (0.18, 1.24)

1

Table 11 Cont.
Immediate quitters
vs. Never quitters

Delayed quitters
vs. Never quitters

Once quitters vs.
Never quitters

None
Only NRT
Only varenicline
Other
Quit attempt in the past
year
Didn’t try at all
Tried and stayed quit for
<=1 week
Tried and stayed quit
for >1 week, but<= 1
month
Tried and stayed quit
for > 1 month, but <=6
months
Tried and stayed quit
for > 6 months
Allowing smoking at
home
Yes, anywhere
Only in certain rooms &
outdoors
Outdoors only
No, not allowed at all
Presence of other
tobacco users in the
household
Yes, someone who
smokes
Yes, someone who uses
smokeless tobacco
No
Confidence to quit
(scale 1-5)
<3 low
3
4
5
Importance to quit
(scale 1-5)
<=3 low
4

1
1.52 (0.59, 3.88)
1.97 (0.82, 4.74)
2.23 (0.64, 7.74)

1
2.39 (0.90, 6.30)
1.62 (0.62, 4.21)
1.39 (0.33, 5.87)

1
1.71 (0.82, 3.57)
1.83 (0.88, 3.81)
0.98 (0.29, 3.36)

1
0.60 (0.15, 2.47)

1
1.58 (0.44, 5.62)

1
1.81 (0.72, 4.57)

1.62 (0.81, 3.23)

2.09 (0.99, 4.42)

1.09 (0.62, 1.89)

1.82 (0.77, 4.31)

1.45 (0.57, 3.71)

1.99 (1.05, 3.76)

1.59 (0.66, 3.84)

1.58 (0.62, 4.01)

1.99 (1.05, 3.75)

1
0.20 (0.07, 0.56)

1
0.93 (0.41, 2.12)

1
0.67 (0.36, 1.23)

1.10 (0.55, 2.17)
0.70 (0.25, 1.96)

0.88 (0.43, 1.81)
0.94 (0.36, 2.48)

0.43 (0.26, 0.73)

1

1

1

5.03 (1.07, 23.65)

3.87 (0.73, 20.59)

0.33 (0.03, 3.50)

1.46 (0.83, 2.55)

1.05 (0.59, 1.87)

1.31 (0.85, 2.00)

1
1.68 (0.63, 4.53)
1.51 (0.55, 4.12)
1.47 (0.53, 4.07)

1
0.86 (0.31, 2.40)
1.11 (0.41, 2.99)
1.29 (0.50, 3.37)

1
0.96 (0.47, 1.95)
1.29 (0.65, 2.59)
1.14 (0.57, 2.29)

1
0.90 (0.28, 2.83)

1
1.13 (0.24, 5.41)

1
0.44 (0.16, 1.19)

5

1.08 (0.38, 3.11)

2.49 (0.61, 10.18)

0.84 (0.35, 2.02)

Pharmacotherapy used
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0.66 (0.33, 1.32)

Due to missing information of baseline characteristics from some patients, only
1007 patients were included in the first multivariate model. Since the loss was 32%
of the overall sample, we compared the characteristics of the included and the
excluded using chi-square test. The results of the comparison are presented in
Table 12. Compared to the excluded, more included patients were middle-aged,
and a greater proportion of them used tobacco every day, used tobacco
cigarettes, pipes, and chew/dip in the past 30 days instead of only cigarettes,
tried to quit in the past year, and scored higher on the scale of
confidence/importance to quit.
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Table 12 Comparison of Excluded Patients Due to Missing Information with Patients
Included in Multivariate Analysis
Included
participants
(N=1007)

Excluded
participants
(N=479)

Age

Chi-square test: pvalue
0.03

<18 years

34 (3.4%)

15 (4.0%)

18-34 years
35-44 years
45-54 years
55-64 years
>=65 years
Gender

241 (23.9%)
227 (22.5%)
261 (25.9%)
188 (18.7%)
56 (5.6%)

71 (18.9%)
68 (18.1%)
113 (30.1%)
75 (20.0%)
33 (8.8%)

Female
Male
Education level

559 (55.5%)
448 (44.5%)

Eighth grade or less
Some high school or high
school
Some college or college
or college above
Use tobacco every day

39 (3.9%)
503 (50.0%)

19 (5.7%)
149 (45.0%)

465 (46.2%)

163 (49.2%)

No
yes
Tobacco use pattern in
the past 30 days
Only cigarettes
Cigarettes, pipes, and
chew/dips
Other
Modified fagerstrom
score
0-2 low dependence
3
4
5-6
Pharmacotherapy used

28 (2.8%)
979 (97.2%)

None
Only NRT
Only varenicline
Other

200 (19.9%)
397 (39.4%)
357 (35.5%)
53 (5.3%)

0.96
196 (55.4%)
158 (44.6%)
0.15

0.005
22 (6.0%)
346 (94.0%)
<0.0001
542 (53.8%)
400 (39.7%)

199 (53.4%)
116 (31.1%)

65 (6.5%)

58 (15.6%)
0.99

275 (27.3%)
291 (28.9%)
282 (28.0%)
159 (15.8%)

64 (27.8%)
67 (29.1%)
65 (28.3%)
34 (14.8%)
0.07
56 (16.2%)
164 (47.4%)
110 (31.8%)
16 (4.6%)
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Table 12 Cont.
Included
participants
(N=1007)
Quit attempt in the past
year
Didn’t try at all
Tried and stayed quit for
<=1 week
Tried and stayed quit
for >1 week, but<= 1
month
Tried and stayed quit
for > 1 month, but <=6
months
Tried and stayed quit
for > 6 months
Allowing smoking at
home
Yes, anywhere
Only in certain rooms &
outdoors
Outdoors only
No, not allowed at all
Presence of other
tobacco users in the
household
Yes, someone who
smokes
Yes, someone who uses
smokeless tobacco
No
Confidence to quit
(scale 1-5)
<3
3
4
5
Importance to quit
(scale 1-5)
<=3
4
5

Excluded
participants
(N=479)

Chi-square test: pvalue
0.01

271 (26.9%)
74 (7.4%)

95 (33.7%)
26 (9.2%)

318 (31.6%)

60 (21.3%)

156 (15.5%)

47 (16.7%)

188 (18.7%)

54 (19.2%)
0.09

456 (45.3%)
135 (13.4%)

177 (49.0%)
40 (11.1%)

299 (29.7%)
117 (11.6%)

90 (24.9%)
54 (15.0%)
0.26

441 (43.8%)

145 (40.4%)

23 (2.3%)

13 (3.6%)

543 (53.9%)

201 (56.0%)
<0.0001

168 (16.7%)
264 (26.2%)
270 (26.8%)
305 (30.3%)

169 (35.3%)
93 (19.4%)
97 (20.3%)
120 (25.1%)
<0.0001

60 (6.0%)
127 (12.6%)
820 (81.4%)

125 (26.1%)
54 (11.3%)
300 (62.6%)
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Elements of an effective tobacco cessation intervention
A total of 11 pharmacists provided the service to 25 patients or more, therefore,
were selected for the interview. We successfully interviewed 8 selected
pharmacists including the pharmacist from pharmacy 8 who achieved a quit rate
of 59.4%. Their responses to the interview questions are summarized in Table 13.

Pharmacists in Table 13 were listed in an ascending order of 6 months quit rate.
A pattern of quit rate and intervention intensity could be identified. Pharmacists
who followed up with patients more frequently and spent more time helping them
achieved higher quit rates than others. Pharmacist 8 met with each group weekly
in the first 3 months and then every 2 weeks for another 3 months. Most
pharmacists reported that they had difficulties in following up with patients. The
most frequently reported reason for loss to follow-up was patients’ lack of
success in quitting tobacco. One pharmacist pointed out that providing free
pharmacotherapy would help keep patients in the program. Another pharmacist
thought that the patients were not invested enough for them to be successful.
Two pharmacists considered inability to provide the full 6-month free
pharmacotherapy as a barrier for them to providing the service. Pharmacist 8 did
not find following up patients difficult. He stressed that the key was to make sure
at the beginning that patients were committed to quit and willing to take time to
attend group meetings. Most pharmacists believed that commitment to life style
changes rather than the tobacco cessation product was the most important
determinant of patients’ success. Pharmacist 8 reported care and
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encouragement from peers in group as the main thing that helped patients quit.
What he did was to put patients of comparable level into same group and have
them work together.

All the pharmacists interviewed utilized or at least incorporated part of the
TUPAC protocol into their counseling. Except the pharmacist from store 8, all the
other pharmacists counseled patients individually and provided some sort of
additional resources to patients such as the 1-800-quitline, behavioral
modification sheet, and literature from American Cancer Society. Pharmacist 8
adopted group meetings as the format of counseling. In addition to counseling,
he also referred patients to the 1-800-Quitline and had group members share
their personal phone numbers for mutual support. Time constraints were the
barrier reported most frequently by the pharmacists. Except pharmacist 8, all the
other pharmacists unanimously agreed that pharmacists had more advantages in
providing tobacco cessation services compared with other health professionals.
They believed that they were better candidates because they were equipped with
knowledge of medications, they were more accessible, and they understood
patients’ needs and life better than any other health professionals. Pharmacist 8
thought that any health professionals willing to take the time and effort would be
a good candidate for providing tobacco cessation services, but he did consider
the relative easy accessibility as an advantage on pharmacists’ side.
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Table 13 Summary of Pharmacists’ Responses to the Interview Questions
Major thing
that
prevents
patients
from
quitting
Uncommitted
to quitting

Barriers
for
providing
the
service

RPh’s
advantages
of proving
TC service

Time
constraints

Committed to
quitting,
regular
communication
with RPh

Lack of
motivation,
life stress

Time
constraints

Accessible;
knowledge
about
medications,
and patients’
medical
history and
life
Knowledge of
medication

Motivation;
social support

Uncommitted
to life-style
changes,
stress

Time
constraints

Readiness to
quit

Uncommitted
to behavioral
modifications

Financial,
patients
not willing
to pay out
of pocket

RPh from
Pharmacy #
(6 mo quit
rate)

Pharmacy
type/# of
prescriptions
filled per day

Initial
contact

Follow-ups

Difficulties in
following up
with patients/
reason of loss
to follow up

Major thing
that keeps
patients quit

P7 (1.1%)

Independent;400
prescriptions

45-min
counseling
in person

One 15 mins
scheduled; two
or three informal
chats lasted
around 5 mins

NA

Life-style
changes

P5 (2.9%)

Chain;80-100
prescriptions

30 mins-1
hour
counseling
in person

1 mo, 3 mo, 6
mo f/u: 5-10
mins in person;
phone call
monthly

P16 (6.7%)

Independent;
90 prescriptions

45 mins-1.5
hours
counseling

P2 (11.5%)

Clinical;
8 prescriptions

45 mins-1
hour
counseling

1 mo and 6 mo
20 mins f/u: 80%
via phone;
additional 10
mins f/u with
several patients
At least three 510 mins phone
calls

Difficult when
having many
patients at the
same time;
Reasons: time
constraints,
unsuccessful
Difficult.
Reasons:
unsuccessful

Sometime
difficult.
Mobility of the
population,
unsuccessful
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Accessible;
knowledge of
medications;
ability to
communicate
with patients
Experienced
in conveying
this type of
information to
patients;
understand
patients’
needs

Table 13 Cont.
RPh from
Pharmacy
# (6 mo
quit rate)

Pharmacy
type/# of
prescription
s filled per
day
Chain;500
prescriptions

Initial
contact

Follow-ups

45 mins-1
hour
counseling
in person

Three 15 mins
f/u via phone;
Additional 1530 mins
meeting with
15% patients

P3 (29.6%)

Independent;
250
prescriptions

45 mins-1
hour
counseling
in person

Minimum of 4
times 40 mins
in person f/u,
mostly monthly

P8 (59.4%)

Long-term
care; 37
prescriptions

30-40 mins
counseling
in person

P1 (22.8%)

1-3 mo: 30-60
mins group
meeting every
week;
4-6 mo: 40-45
mins group
meeting every
two weeks;
After 6 mo:
continue to
meet monthly if
patients want;
All in person
P#: pharmacist from pharmacy #; RPh: pharmacist

Difficulties in
following up with
patients/ reason
of loss to follow
up
Difficult to have
patients come in;
Reasons:
telephone
disconnected, not
taking phone calls
Not difficult. If
patients miss an
appointment, they
are out of the
program.
Reasons:
unmotivated, high
nicotine
dependence, side
effects of therapy
Not difficult. The
key is to make sure
at the beginning
that they are
committed to quit.
Encouragement
from peers in the
group also plays a
role in keeping
patients in the
group.
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Major thing
that keeps
patients
quit
Understandi
ng the
addiction,
how the
therapy
work, and its
side effects
Committed,
communicati
on with RPh

Care and
encouragem
ent from
peers in the
group

Major thing
that
prevents
patients
from quitting
Program not
financed to
provide the
full 6 month
therapy

Barriers
for
providing
the
service
Couldn’t
provide
free
therapy;
time
constraints

RPh’s
advantages
of proving
TC service

Social
pressure,
presence of
other
smokers

No
barriers

Accessible;
knowledge
about
medication

Lack of
confidence to
quit

Time
constraints

Accessible

Accessible;
ability to
identify
smokers in
pharmacy

In addition to the above findings, we identified a data collection issue that caused
the low quit rate of pharmacy 7. During the conversation with the pharmacist from
pharmacy 7, we found out that in majority he only followed up with patients once
after the initial contact and the only follow-up could happen at 1 month, 3 months,
or 6 months, which would cause missing data for two scheduled visits. Because
we considered missing as failure when analyzing data, his quit rate was
dramatically pulled down due to this issue. Not contacting patients is different
than failure to follow up with them. Among the patients who were not contacted at
the scheduled follow-up times, there must be a proportion of them who were
actually abstinent, so the real quit rates of pharmacy 7 should be higher than
what we calculated according to the data collected. There was a similar issue
with pharmacy 3. This pharmacist met patients face to face for all follow-ups. He
made a rule with patients that he would stop providing the service for them if they
missed a single appointment with him. He stopped following up with the patients
who broke the rule and then these patients were shown as missing for the later
follow-ups in the data. This issue decreased the calculated quit rate for pharmacy
3.
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Chapter 5 Discussion and conclusions
Although tobacco use has been recognized as a health hazard since last century,
it remains a major public health concern in the United States. Tobacco use is one
of the Healthy People 2020 topic areas retained from Healthy People 2010.
Healthy People 2020 tobacco use objectives are organized in 3 key goals:
reducing prevalence of tobacco use, implementing health care system changes,
and enhancing social and environmental changes. New from Healthy People
2010, under health care system changes, two new objectives have been added
to Healthy People 2020, specifically increasing tobacco screening in health care
settings by 10 percent and increasing tobacco cessation counseling in health
care setting by 10 percent.97 Considering the attributable deaths to tobacco use
were almost as many as the attributable deaths to the world’s number two killer
cerebrovascular diseases, reducing tobacco use has become an imperative
task.98 A pharmacists-assisted tobacco cessation service in UK had a quit rate of
3.6% at 52 weeks. An economic evaluation of the service showed that it was
cost-effective regardless of the relatively low quit rate.34 The reported incremental
cost per quality adjusted life years (QALY) for one to one pharmacist counseling
is 2,600 euros, which is only one-tenth of the cost-effectiveness threshold set by
National Institute for Health and Clinical Excellence (NICE).99
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Discussion of study results
The study findings on the program effectiveness add information to the literature
regarding community pharmacists’ capacity of delivering tobacco cessation
services. Comparing to the quit rates of previous pharmacists-assisted programs
or programs led by other health professionals, the average quit rates achieved by
the NMPCF program are not inferior regardless of the conservative calculation
approach we took and the data collection issues. Pharmacy 8 achieved a 6month point prevalence quit rate of 59.4%, which is rarely seen in the literature.
The achieved quit rate by the program proves that pharmacists are capable of
delivering effective tobacco cessation services.

Although there have been studies of pharmacists-assisted smoking cessation
programs, the majority of them focused on demonstrating success rates in a
cross-sectional manner. Our findings from the survival analysis present a
longitudinal picture of patients’ quitting experiences. The dramatic decrease in
quit rate occurred in the first two weeks indicates a clinically critical window of
relapse and the needs of enhancing intervention in early period of interventions.
According to TTM, our results suggests that a large proportion of patients would
experience a relapse from “action” stage back to “preparation” or even
“contemplation” at the beginning of quitting, and timely support corresponding to
this relapse is needed to help patients through this relapse.
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Previous studies mainly focused on adults and rarely included adolescents as
study subjects. We had 49 teenagers in the study sample. The results of log rank
test showed that patients under 18 years old had a better quitting experience and
were more likely to be abstinent continuously. It was within our expectation that
patients only used NRT or only used varenicline had higher probability of being
continuously quit over time compared to patients who quit without any
pharmaceutical aid or those who tried several different products. The
effectiveness of NRT and varenicline has been demonstrated by clinical trials
and many observational studies. Although we had no data to explain why some
patients kept changing products, we believed that switching products was an
indicator of their lack of success in quitting tobacco. One pharmacist we
interviewed pointed out that those patients who blamed products were usually
uncommitted to behavioral modifications and unlikely to be successful. We did
not find any study from the literature that assessed the relationship between type
of tobacco and the risk of relapse. It has been argued that using smokeless
tobacco is of less health hazard than cigarettes smoking because it does not
expose tobacco users to toxic combustion gases and particles that are
responsible for most tobacco induced diseases.100, 101 Patients who used multiple
tobacco products might pay more attention to their health and might be more
aware of the health harms of tobacco, therefore more committed to quitting
tobacco use. Future studies are needed to verify our finding that patients who
used cigarettes, pipes, chew/dips had a higher probability of being continuously
quit than those who only smoked cigarettes.

90

As we stressed in the results, the estimates of hazard ratios from the Cox
proportional hazard model presented in Table 6 were biased towards the null due
to the violation of the assumption of proportionality. It is actually more realistic
that the impact of age, pharmacotherapy, and tobacco use reduces over time
considering quitting tobacco is a difficult task. Although our assignment of the
time of continuous abstinence could influence the hazard ratios, we do not think it
is the cause of the assumption violation because the same assignment
schematic was consistently and systematically applied to all patients. We
assumed that patients’ early responses about their continuous abstinence were
more reliable and accurate. We presumed that the period during which patients
were continuously abstinent could not be longer that the duration between the
intake day and the day they reported that they had used tobacco. We assumed
that those who failed to respond to the question “Have you ever used tobacco
once since your quit date” at any of the three follow-ups did not quit for even one
day and assigned zero day as their time of continuous abstinence. All these
three assumptions are fairly conservative and would only underestimate the time
of continuous abstinence.

The goal of the pattern analysis was to characterize patients with different
quitting patterns, therefore the results from the multivariate model without
pharmacy stores included should be used for interpretation. Pharmacy store here
is a proxy for the intervention patients received, which is inevitably related to
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some patient characteristics such as pharmacotherapy used, importance to quit,
and confidence to quit. Enhancing patients’ confidence and perceived importance
to quit is part of the counseling intervention. Pharmacies that successfully
improved patients’ confidence and importance to quit would be shown to have
relatively more IQ, DQ, and OQ than others. Including pharmacy in the model, a
portion of the variance explained by pharmacotherapy used and importance and
confidence to quit would be shared by pharmacy and the ORs for these variables
would be changed. The main purpose of building a second model with pharmacy
included was to demonstrate that the variation in quit rates across pharmacies
could not be fully explained by the difference in patients recruited. This point was
proved by the results of the second model and verified through the interviews
with participating pharmacists. In fact, pharmacy appeared to be the strongest
predictor of patients’ likelihood of achieving abstinence in terms of magnitude of
ORs and consistency of statistical significance across comparisons from IQ to
OQ. This confirmed our hypothesis that the tobacco cessation intervention
patients receive also impacts their chance of successfully quitting tobacco.

The results of the pattern analysis showed the existence of different quitting
patterns among tobacco users. Conceptualizing the findings with TTM, we could
infer that participants were at different stages of quitting tobacco when recruited,
spreading among “precontemplation”, “contemplation” and “preparation”. People
who achieved immediate success (IQ) were possibly in “preparation” at
recruitment and were ready to make a change. Those who were in
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“precontemplation” or “contemplation” needed time and help from pharmacists
before taking the action to quit, which makes them more likely to be delayed
quitters and once quitters. Reviewing the results of the pattern analysis, it is also
clear that patients with each quitting pattern have different characteristics. As
proposed by health belief model, the likelihood of a tobacco user taking action to
quit is determined by 3 factors, namely perceived benefits of quitting, perceived
barriers of quitting, and perceived threat of not quitting. These 3 factors are in
turn influenced by demographic factors, confidence and importance to quit,
nicotine dependence, experiences of past quitting attempts, and availability of
pharmacotherapy. More importantly, the results of the second model, with
pharmacy being the strongest predictor of success, suggest that patients’
perception of benefits and barriers of quitting and threats of continuing smoking
can be changed by pharmacists’ intervention. By changing patients’ perceived
benefits, barriers and threats, pharmacists helped patients move along the
stages from “precontemplation”, “contemplation”, and “preparation” to “action”
and get ready to quit.

In general, our findings in the predictors of quitting patterns fit health belief model
well.102 For instance, patients with higher education are likely to have a deeper
perception regarding the threats and health dangers of tobacco use, therefore
are more likely to quit. Nevertheless, we have some results that cannot be
understood intuitively and are discussed below. Although the existing literature
cannot explain why the association between age under 18 and being IQ was still
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present and strong after adjusting for level of nicotine dependence,
pharmacotherapy used, type of tobacco, confidence to quit and other patient
characteristics, we believed that it was plausible. Adolescent smokers were more
likely to respond to increased price of cigarettes.
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Income, an important factor

that would affect adolescents’ ability to purchase tobacco, was not included in the
model due to substantial missing data for this variable. Our findings on home ban
of smoking and importance to quit in the pattern analysis contradict with the
existing literature, but we do not find them entirely implausible. Patients who
were not allowed to smoke at home or only allowed to smoke in certain rooms
were less likely to be IQ than those who were allowed to smoke anywhere at
home. Social support is important for someone to be successful in quitting
tobacco. Being able to smoke at home might be an indicator of harmonious
domestic relationship and family support. Most of the pharmacists we interviewed
stressed that personal commitment to quitting is the most important determinant
of successful abstinence. Another potential explanation is that those patients are
more determined to quit. Their decision to quit comes from themselves rather
than family members. Importance to quit might not be necessarily related to how
committed a patient is. The patients scored high importance might have health
conditions that forced them to quit, but it does not mean that they were ready to
quit. Unfortunately, we were unable to examine the effects of health related
factors due to lack of such information.
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We compared those who had missing data at 6 months follow-up with those who
were followed up successfully by pharmacists and reported that they failed to quit
in terms of baseline characteristics. We performed chi-square tests and found
that they were similar in all the baseline characteristics except for
pharmacotherapy (p<0.0001) and home ban of smoking (p=0.01). A greater
proportion of the patients who were missing did not use any pharmacotherapy
aid to help them quit compared to those who self-reported themselves being
unsuccessful (21.9% vs. 9.6%). Also, a greater percentage of them were allowed
to smoke anywhere at home (14.6% vs. 6.7%). When compared to patients who
were abstinent at 6 months follow-up, the lost to follow-ups differed in many
aspects, including age, education level, tobacco use in the past 30 days, quit
attempts in the past year, confidence to quit, and number of cigarettes smoked
per day. The similarity in patient characteristics between the lost to follow-ups
and the ones who were self-reported being unsuccessful supports our
assumption that lost to follow-ups were most likely to be continued tobacco users
at the 3 scheduled follow-ups.

The interviews with pharmacists further demonstrated the importance of the
tobacco cessation service. Although we could not perform statistical analyses on
the pharmacists’ responses due to the limited number of interviews conducted, a
pattern between high quit rates and intensive interventions and frequent followups can be inferred. Pharmacist 8 met with patients in groups as often as once a
week in the first 3 months of the program. This finding is not only consistent with
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the current literature, but also supports our point regarding the necessity of
reinforcing treatment effects in early period of an intervention. Pharmacist 8 was
the only one who adopted group meetings as the format of counseling among all
the pharmacists interviewed. As the existing literature suggests, his success
might also be related to the format of group counseling. In fact, pharmacist 8
considers group support and encouragement as the major factor that helps
patients quit.

It is obvious that, to some extent, all the pharmacists delivered the service
differently, with some of them providing more intensive interventions than others.
However, they do share some common perceptions of tobacco cessation and the
service they provided. Four of the seven pharmacists interviewed believe that
behavioral modifications are the most important component of a tobacco
cessation service and patients’ commitment to the modifications largely
determines whether they would be successful or not.

Even though tobacco cessation counseling with pharmacists is not covered by
medical insurance yet and Healthy People 2020 does not specifically state
increasing tobacco cessation counseling in pharmacy setting as an objective,
pharmacists might actually be better candidates for delivering this kind of service
compared to other health professionals. Apart from the fact that pharmacists are
capable of delivering effective tobacco cessation services if given with right
training, the pharmacists we interviewed unanimously responded that they were
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the best choice for delivering the service. Quitting tobacco is a challenging task
that takes time and requires social support. Having a health professional who
understands the addiction and have an intimate knowledge of patients’ medical
history and life would help ease the task. Pharmacists seem to fit this description
equally or better than any other health care providers.
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Study limitations
Our study has several limitations. The major limitation is that nearly 50% missing
on patients’ smoking status occurred at all three follow-ups. We presume that the
missing is mainly due to patients’ lack of success and data collection problems.
The majority of the pharmacists believed that loss to follow-up happened
because the patient started to use tobacco again. The primary goal of the
program was not for conducting research, therefore data collection was not a
priority during the implementation of the program. There were two data collection
issues. Pharmacist 3 and 7 did not follow up with patients as indicated by
protocol, which contributed loss to follow-ups. Missing information on
continuous abstinence status also caused 456 subjects being censored right at
the beginning of the observation in the survival analysis. Although this censorship
did not bias the results among patients who completed at least one follow-up,
loss of statistical power could not be prevented. Missing on follow-up dates and
length of continuous abstinence was also the reason that we had to make
assumptions when assigning the time of abstinence, which is the second
limitation of this paper. Even though we made the data assumptions carefully and
conservatively, there is no way to test these assumptions. Lastly, the data was
limited to what was on the intake questionnaire, so the multivariate pattern
analysis did not include other potentially relevant variables such as general
health and morbidities.
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Study strengths
Despite the limitations, our study provides valuable information and has strengths
over previous studies. Compared to the pharmacists-assisted tobacco cessation
programs reported in the literature, our study sample, consisting of 1486 patients,
is unprecedentedly large. Other than calculating point prevalence success rates,
we also presented quit rates from a longitudinal perspective and used time to
relapse as a unit of analysis instead of a “quit or not” dichotomous outcome.
Despite of the importance of understanding quitting process, there have been
very few studies that assessed quitting process or characterized quitting patterns
emerged during quitting attempts. Our study is one of the few studies that
assessed patients’ quitting experience longitudinally. Additionally, observing and
studying how patients’ quitting-behaviors change during or after intervention
would enable researchers to understand the process of quitting, identify critical
windows during which smokers are most likely to relapse, and tailor interventions
to patients’ needs. Our study contributes to this body of knowledge by
characterizing quitting patterns presented by the patients in the program,
comparing patients with different patterns with respect to their characteristics,
and identifying critical windows of relapse. Moreover, our findings in quitting
patterns provide background knowledge for future studies to reveal the changes
or events behind each pattern, which in turn, would further enhance our
understanding of quitting process and enable individualized interventions. In
addition, to our best knowledge, intra-program variation in effectiveness and the
reasons behind the heterogeneous success rates in a same program have never
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been explored before. Our findings would enhance the understanding of what
makes an effective intervention and provide useful information for improving
future interventions.
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Conclusions
Pharmacists are capable of delivering tobacco cessation services. Patients’
likelihood of quitting tobacco depends both on themselves and the intervention
they receives. Intensive counseling and close follow-up are important elements of
an effective tobacco cessation intervention. Most of the pharmacists that
provided the program believe that commitment to behavioral modifications is the
most important determinant of one’s success in quitting tobacco.

Different quitting patterns exist among patients. For each pattern, the patients
have distinctive characteristics in terms of level of nicotine dependence,
pharmacotherapy used, motivational factors and demographic factors. Future
research is needed to study quitting patterns more closely and to find out, apart
from patient characteristics, the reasons for observing different quitting patterns
among patients.
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Appendices
Appendix A Fagerstrom Test of Nicotine Dependence (FTND)
Appendix B Interview Script
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Appendix A

Fagerstrom Test of Nicotine Dependence (FTND)
1- How soon after you wake up do you smoke your first cigarette?
Within 5 minutes--3
6-30 minutes—2
31-60 minutes--1
after 60 minutes--0
2- Do you find it difficult to refrain from smoking in places where it is
forbidden, e.g. at the mosque (church), at the bus?
Yes--1
No--0
3- Which cigarette would hate most to give up?
The first one in the morning--1
All others--0
4- How many cigarettes/day do you smoke?
31 or more—3
21-30--2
11-20--1
10 or less--0
5- Do you smoke more frequently during the first hours after waking than the
rest of the day?
Yes--1
No--0
6- Do you smoke when you are so ill that you are in bed most of the day?
Yes--1
No—0
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Appendix B

Interview Script

Part I-Pharmacy
1. Type of pharmacy (independent, chain, or other?)

2. Including you, how many pharmacists are employed in this pharmacy?

3. On average, how many prescriptions does your pharmacy fill each day?

Part II-Pharmacist

1. Have you done smoking cessation counseling other than the NMPHA
program?

2. Was there a packet you use or protocol you follow to help patients quit?
Can you tell me what the packet/protocol contains?

3. About how many times did you follow up with each patient you manage in
the course of the program?

4. Was there any contact outside of follow-up schedule?

5. How long did the initial contact and each follow-up last?

104

6. What approaches did you use to follow up with patients? (face-to-face
follow-up, via telephone, or other)

7. Did you find it difficult to follow-up with patients? How did loss to follow-up
happen (give top 3 reasons)?

8. What was the form of the counseling? (group based or individually?)

9. What kind of resources did you provide to patients?

10. What is the major thing that you think that helps keep patients quit?

11. What is the major thing that you think that prevents patients from quitting?

12. What were the barriers for you to providing the service?
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13. Compared to other health professionals, do you think that pharmacists
have more advantages for delivering tobacco cessation services? Can
you tell me why?

14. Is there anything I have not mentioned that you would like to tell me?
(e.g. important things you did in practice for helping patients quit)
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